<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">EBioMedicine</journal-id><journal-id journal-id-type="iso-abbrev">EBioMedicine</journal-id><journal-title-group><journal-title>EBioMedicine</journal-title></journal-title-group><issn pub-type="epub">2352-3964</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26137510</article-id><article-id pub-id-type="pmc">4457350</article-id><article-id pub-id-type="publisher-id">S2352-3964(14)00025-5</article-id><article-id pub-id-type="doi">10.1016/j.ebiom.2014.11.001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Mild Electrical Stimulation with Heat Shock Reduces Visceral Adiposity and Improves Metabolic Abnormalities in Subjects with Metabolic Syndrome or Type 2 Diabetes: Randomized Crossover Trials</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kondo</surname><given-names>Tatsuya</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="fn0005" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Ono</surname><given-names>Kaoru</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="fn0005" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Kitano</surname><given-names>Sayaka</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="fn0005" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Matsuyama</surname><given-names>Rina</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Goto</surname><given-names>Rieko</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Suico</surname><given-names>Mary Ann</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Kawasaki</surname><given-names>Shuji</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Igata</surname><given-names>Motoyuki</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Kawashima</surname><given-names>Junji</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Motoshima</surname><given-names>Hiroyuki</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Matsumura</surname><given-names>Takeshi</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Kai</surname><given-names>Hirofumi</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Araki</surname><given-names>Eiichi</given-names></name><email>earaki@gpo.kumamoto-u.ac.jp</email><xref rid="af0005" ref-type="aff">a</xref><xref rid="cr0005" ref-type="corresp">&#x0204e;</xref></contrib></contrib-group><aff id="af0005"><label>a</label>Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan</aff><aff id="af0010"><label>b</label>Department of Molecular Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan</aff><author-notes><corresp id="cr0005"><label>&#x0204e;</label>Corresponding author at: Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-Ward, Kumamoto 860-8556, Japan. <email>earaki@gpo.kumamoto-u.ac.jp</email></corresp><fn id="fn0005"><label>1</label><p id="np0005">TK, KO and SK have contributed equally to this work and share first authorship.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>11</day><month>11</month><year>2014</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>11</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>11</day><month>11</month><year>2014</year></pub-date><volume>1</volume><issue>1</issue><fpage>80</fpage><lpage>89</lpage><history><date date-type="received"><day>17</day><month>9</month><year>2014</year></date><date date-type="rev-recd"><day>4</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>4</day><month>11</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014 The Authors</copyright-statement><copyright-year>2014</copyright-year><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).</license-p></license></permissions><abstract><sec><title>Background</title><p>The induction of heat shock protein (HSP) 72 by mild electrical stimulation with heat shock (MES&#x000a0;+&#x000a0;HS), which improves visceral adiposity and insulin resistance in mice, may be beneficial in treating metabolic syndrome (MS) or type 2 diabetes mellitus (T2DM).</p></sec><sec><title>Methods</title><p>Using open-label crossover trials, 40 subjects with MS or T2DM were randomly assigned using computer-generated random numbers to 12&#x000a0;weeks of therapeutic MES&#x000a0;+&#x000a0;HS followed by 12&#x000a0;weeks of no treatment, or vice versa. During the intervention period, physical and biochemical markers were measured.</p></sec><sec><title>Findings</title><p>Compared to no treatment, MES&#x000a0;+&#x000a0;HS treatment was associated with a significant decrease in visceral adiposity (&#x02212;&#x000a0;7.54&#x000a0;cm<sup>2</sup> (&#x02212;&#x000a0;8.61%), 95% CI &#x02212;&#x000a0;8.55 to &#x02212;&#x000a0;6.53 (p&#x000a0;=&#x000a0;0.037) in MS, &#x02212;&#x000a0;19.73&#x000a0;cm<sup>2</sup> (&#x02212;&#x000a0;10.89%), 95% CI &#x02212;&#x000a0;20.97 to &#x02212;&#x000a0;18.49 (p&#x000a0;=&#x000a0;0.003) in T2DM). Fasting plasma glucose levels were decreased by 3.74&#x000a0;mg/dL (&#x02212;&#x000a0;5.28%: 95% CI &#x02212;&#x000a0;4.37 to &#x02212;&#x000a0;3.09&#x000a0;mg/dL, p&#x000a0;=&#x000a0;0.029) in MS and by 14.97&#x000a0;mg/dL (10.40%: 95% CI &#x02212;&#x000a0;15.79 to 14.15&#x000a0;mg/dL, p&#x000a0;&#x0003c;&#x000a0;0.001) in T2DM, and insulin levels were also reduced by 10.39% and 25.93%, respectively. HbA1c levels showed a trend toward reduction (&#x02212;&#x000a0;0.06%) in MS, and was significantly declined by &#x02212;&#x000a0;0.43% (95% CI &#x02212;&#x000a0;0.55 to &#x02212;&#x000a0;0.31%, p&#x000a0;=&#x000a0;0.009) in T2DM. HbA1c level of less than 7.0% was achieved in 52.5% of the MES&#x000a0;+&#x000a0;HS-treated T2DM patients in contrast to 15% of the non-treated period. Several insulin resistance indices, inflammatory cytokines or adipokines, including C-reactive protein, adiponectin, and tumor necrosis factor-&#x003b1;, were all improved in both groups. In isolated monocytes, HSP72 expression was increased and cytokine expression was reduced following MES&#x000a0;+&#x000a0;HS treatment. Glucose excursions on meal tolerance test were lower after using MES&#x000a0;+&#x000a0;HS in T2DM.</p></sec><sec><title>Interpretation</title><p>This combination therapy has beneficial impacts on body composition, metabolic abnormalities, and inflammation in subjects with MS or T2DM. Activation of the heat shock response by MES&#x000a0;+&#x000a0;HS may provide a novel approach for the treatment of lifestyle-related diseases.</p></sec><sec><title>Funding</title><p>Funding for this research was provided by <funding-source id="gts0005">MEXT KAKENHI</funding-source> (Grants-in-Aid for Scientific Research from Ministry of Education, Culture, Sports, Science and Technology, Japan).</p></sec></abstract><abstract abstract-type="author-highlights"><title>Highlights</title><p><list list-type="simple"><list-item id="u0005"><label>&#x02022;</label><p>We report the use of mild electrical stimulation with heat shock (MES&#x000a0;+&#x000a0;HS) in treating metabolic syndrome or type 2 diabetes.</p></list-item><list-item id="u0010"><label>&#x02022;</label><p>The treatment improves visceral adiposity, glucose homeostasis, insulin resistance and chronic inflammatory status.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p>Our findings suggest that MES&#x000a0;+&#x000a0;HS might be a valuable therapeutic option for patients with these lifestyle-related diseases.</p></list-item></list></p></abstract><kwd-group><title>Keywords</title><kwd>Metabolic syndrome</kwd><kwd>Type 2 diabetes</kwd><kwd>Heat shock response</kwd><kwd>Insulin resistance</kwd><kwd>Chronic inflammation</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p>Although DCCT, UKPDS and our Kumamoto Study (<xref rid="bb0005" ref-type="bibr">Shichiri et al., 2000</xref>) have shown that strict glycemic control could prevent microvascular complications, the increase of diabetes is still an important issue worldwide. The increase of type 2 diabetes mellitus (T2DM) is associated with excess visceral adiposity, which is tightly linked to metabolic syndrome (MS). MS is recognized as a cluster of cardiovascular risk factors such as hyperglycemia, dyslipidemia, elevated blood pressure and chronic inflammation (<xref rid="bb0010" ref-type="bibr">Alberti et al., 2005</xref>). Visceral fat has been demonstrated to express more pro-inflammatory cytokines than subcutaneous fat in obese states (<xref rid="bb0015" ref-type="bibr">Ohman et al., 2009</xref>). Inflammatory markers such as C-reactive protein (CRP) (<xref rid="bb0020" ref-type="bibr">Tamakoshi et al., 2003</xref>) and tumor necrosis factor (TNF)-&#x003b1; have been linked to MS.</p><p>Currently, there are no medications or modalities to reduce both visceral adiposity as well as chronic inflammation in MS or T2DM subjects. Recently, we (<xref rid="bb0025" ref-type="bibr">Morino et al., 2008a</xref>, <xref rid="bb0030" ref-type="bibr">Adachi et al., 2010</xref>) and others (<xref rid="bb0035" ref-type="bibr">Chung et al., 2008</xref>, <xref rid="bb0040" ref-type="bibr">Gupte et al., 2009</xref>) have shown that the beneficial metabolic advantages of heat shock response (HSR) activation, which appears to mainly involve heat shock protein (HSP) 72. HSP72 induction by mild electrical stimulation (MES) with heat shock (HS) (<xref rid="bb0025" ref-type="bibr">Morino et al., 2008a</xref>, <xref rid="bb0045" ref-type="bibr">Kondo et al., 2012</xref>), a transgenic system (<xref rid="bb0035" ref-type="bibr">Chung et al., 2008</xref>), heat treatment (<xref rid="bb0040" ref-type="bibr">Gupte et al., 2009</xref>, <xref rid="bb0050" ref-type="bibr">Kavanagh et al., 2011</xref>) or chemical inducers (<xref rid="bb0030" ref-type="bibr">Adachi et al., 2010</xref>) ameliorated abnormal metabolic features in animal models of T2DM, such as insulin resistance, hyperglycemia and visceral fat accumulation. Mild electrical stimulation enhances heat induction of HSP72 (<xref rid="bb0055" ref-type="bibr">Morino et al., 2008b</xref>) and may directly activate insulin signaling by modulating the insulin receptor localization of membrane components (<xref rid="bb0060" ref-type="bibr">Yano et al., 2010</xref>, <xref rid="bb0065" ref-type="bibr">Morino-Koga et al., 2013</xref>). In this study, we investigated the effects of MES&#x000a0;+&#x000a0;HS on glucose homeostasis, insulin resistance, visceral adiposity and inflammatory cytokine levels in male subjects with MS or T2DM. In addition, inflammatory characteristics of circulating monocytes were examined. This novel combination therapy may provide an additional treatment strategy to improve metabolic abnormalities in lifestyle-related diseases.</p></sec><sec id="s0010"><label>2</label><title>Materials and Methods</title><sec id="s0015"><label>2.1</label><title>Study Participants</title><p>A total of 40 Japanese males with MS or T2DM were recruited. MS was defined by the Examination Committee for Criteria of Metabolic Syndrome and was diagnosed on the basis of the criteria of the American Diabetes Association. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki, and written informed consent was obtained from each subject. These researches were approved by the Ethics Review Committee at Kumamoto University (Advanced Ethics No. 736 and Ethics No. 514). These clinical trials were registered with an approved ICMJE clinical trial registry, UMIN (ID: UMIN 000001149, 000003210 and 000007792). Protocol details can be found in the Supplemental materials.</p></sec><sec id="s0020"><label>2.2</label><title>MES&#x000a0;+&#x000a0;HS Treatment</title><p>The devices (BioMetronome&#x000ae;) for producing MES&#x000a0;+&#x000a0;HS were provided by Tsuchiya Rubber Co. Ltd. (Kumamoto, Japan). The description of the MES&#x000a0;+&#x000a0;HS device has been provided previously (<xref rid="bb0070" ref-type="bibr">Kondo et al., 2010</xref>). Briefly, MES&#x000a0;+&#x000a0;HS produces electrical stimulation of 1.4&#x000a0;&#x000b1;&#x000a0;0.1&#x000a0;V/cm: the pads were positioned on the front and back of the abdomen, 55 pulses per second, 0.1&#x000a0;millisecond duration with 42&#x000a0;&#x000b0;C heat. The padded area was 15&#x000a0;cm in length&#x000a0;&#x000d7;&#x000a0;25&#x000a0;cm in width.</p></sec><sec id="s0025"><label>2.3</label><title>Randomization and Masking</title><p>Forty eligible MS or T2DM subjects were randomly assigned using computer-generated random numbers into two groups by Latin square method, each containing 20 subjects. Neither subjects nor investigators were masked to treatment allocation at the time of enrollment.</p></sec><sec id="s0030"><label>2.4</label><title>Study Design and Clinical Protocol</title><p>This study was a prospective, randomized, open-label, crossover trial. Forty eligible MS or T2DM subjects were randomly assigned into two groups, each containing 20 subjects. Group I underwent a 12-week intervention period of MES&#x000a0;+&#x000a0;HS followed by 12&#x000a0;weeks with no treatment. The order was reversed in group II. During the MES&#x000a0;+&#x000a0;HS-treatment period, subjects were instructed to use MES&#x000a0;+&#x000a0;HS 4 times a week for 60&#x000a0;min per session. Exercise and diet alterations were prohibited during the entire period. At 0, 12 and 24&#x000a0;weeks, body compositions, abdominal adiposity, metabolic and biochemical examination with a 75&#x000a0;g oral glucose tolerance test (OGTT) in MS or a 592&#x000a0;kcal meal tolerance test (MTT) in T2DM were performed. The primary endpoint is the amount of visceral adiposity and glucose control. Other outcomes include blood pressure, insulin resistance, inflammatory cytokine levels and the HbA1c achievement ratio of less than 7.0%. For the primary outcome, we estimated the need to enroll 36 subjects to detect changes in visceral fat area of 15% with MES&#x000a0;+&#x000a0;HS as compared to no treatment, with statistical power of 80%, allowing for a type I (&#x003b1;) error of 0.05. Allowing for a loss to follow-up rate of 10%, 40 subjects were required to undergo randomization.</p></sec><sec id="s0035"><label>2.5</label><title>Quantification of Adiposity</title><p>Visceral fat area (VFA) and subcutaneous fat area (SFA) at the umbilical level were measured using CT scans (HiSpeed NX/i, GE Healthcare Japan Co., Ltd., Tokyo, Japan).</p></sec><sec id="s0040"><label>2.6</label><title>Insulin Sensitivity Indices</title><p>Several indices were calculated based on the results of OGTT in MS. The quantitative insulin-sensitivity check index (QUICKI), homeostasis model assessment of insulin resistance (HOMA-IR), HOMA-&#x003b2;, composite whole body insulin sensitivity index (cWBISI) and insulinogenic index (I.I.) were determined, as described previously (<xref rid="bb0080" ref-type="bibr">Yamashiro et al., 2010</xref>).</p></sec><sec id="s0045"><label>2.7</label><title>Monocytes Isolation and Analysis</title><p>To investigate the characteristics of monocyte in MS or T2DM subjects, 10 subjects were randomly selected. Before and after 4&#x000a0;weeks of MES&#x000a0;+&#x000a0;HS treatment, blood samples were collected during a fasted state. First, peripheral blood mononuclear cells (PBMCs) were isolated using BD Vacutainer&#x02122; CPT&#x02122; (BD, Franklin Lakes, NJ). Monocytes were subsequently isolated from the PBMCs magnetically by depletion technique (Miltenyl Biotech. Auburn. CA). For some experiments, monocytes were examined before and after activation with lipopolysaccharide (LPS: 160&#x000a0;ng/mL) overnight.</p></sec><sec id="s0050"><label>2.8</label><title>mRNA Expression Determined by qRT-PCR</title><p>Real time qRT-PCR was performed using mRNA from isolated monocytes stimulated with LPS. The protocol of qRT-PCR has been described previously (<xref rid="bb0030" ref-type="bibr">Adachi et al., 2010</xref>).</p></sec><sec id="s0055"><label>2.9</label><title>Statistical Analysis</title><p>Statistical analysis was performed with SPSS software (IBM, Chicago, IL, USA). All values were expressed as mean&#x000a0;&#x000b1;&#x000a0;standard deviation (S.D.). The treatment effects of MES&#x000a0;+&#x000a0;HS were analyzed by paired a <italic>t</italic>-test if data were normally distributed or a Wilcoxon signed-rank test if not. Sequential changes were analyzed by repeated-measures ANOVA. Two-sided p-values of less than 0.05 were considered to indicate statistical significance.</p></sec></sec><sec id="s0060"><label>3</label><title>Results</title><sec id="s0065"><label>3.1</label><title>Characteristics of MS or T2DM Subjects</title><p>Japanese males diagnosed with MS or T2DM were randomly assigned to either group I or group II. Thereafter, subjects were randomized to one of two possible group sequences to receive no treatment or MES&#x000a0;+&#x000a0;HS treatment (<xref rid="f0005" ref-type="fig">Fig.&#x000a0;1</xref>). The baseline values were similar between the two groups (<italic>n</italic>&#x000a0;=&#x000a0;40) (<xref rid="t0005" ref-type="table">Table&#x000a0;1</xref>).</p></sec><sec id="s0070"><label>3.2</label><title>Adverse Effects</title><p>There were no harmful or adverse events including hypoglycemia or biochemical abnormalities during these studies. As only mild electrical current was used, no perceptible muscle contraction or muscle pain was generated in the subjects.</p></sec><sec id="s0075"><label>3.3</label><title>Adipose Tissue Composition and Physical Status</title><p>Visceral and subcutaneous adiposity were analyzed using abdominal CT scans. After MES&#x000a0;+&#x000a0;HS treatment, visceral fat area (VFA) in MS and T2DM was significantly decreased by 12.69&#x000a0;&#x000b1;&#x000a0;3.25&#x000a0;cm<sup>2</sup> (&#x02212;&#x000a0;8.61%, p&#x000a0;=&#x000a0;0.037, <xref rid="t0010" ref-type="table">Table&#x000a0;2</xref>) and 20.88&#x000a0;&#x000b1;&#x000a0;4.00&#x000a0;cm<sup>2</sup> (&#x02212;&#x000a0;10.89%, p&#x000a0;=&#x000a0;0.003. <xref rid="t0010" ref-type="table">Table&#x000a0;2</xref>), respectively. Although there was no change in subcutaneous fat area (SFA) as a result of MES&#x000a0;+&#x000a0;HS treatment, total abdominal adiposity was significantly reduced (<xref rid="t0010" ref-type="table">Table&#x000a0;2</xref>).</p><p>Waist circumference (Wc) also showed similar changes associated with MES&#x000a0;+&#x000a0;HS treatment (<xref rid="t0010" ref-type="table">Table&#x000a0;2</xref>). Although there was no significant change in MS, body mass index (BMI) was significantly decreased by 1.42% (p&#x000a0;=&#x000a0;0.027) in T2DM. Systolic or diastolic blood pressure (SBP or DBP) was significantly reduced both in MS and T2DM (<xref rid="t0015" ref-type="table">Table&#x000a0;3</xref>).</p></sec><sec id="s0080"><label>3.4</label><title>Glucose Homeostasis and Insulin Resistance</title><p>Fasting plasma glucose (FPG) was significantly decreased (&#x02212;&#x000a0;5.95&#x000a0;mg/dL in MS, &#x02212;&#x000a0;15.45&#x000a0;mg/dL in T2DM, <xref rid="t0010" ref-type="table">Table&#x000a0;2</xref>). Fasting immuno-reactive insulin (IRI) showed similar alterations (&#x02212;&#x000a0;1.08&#x000a0;&#x003bc;IU/mL in MS, &#x02212;&#x000a0;3.89&#x000a0;&#x003bc;IU/mL in T2DM, <xref rid="t0010" ref-type="table">Table&#x000a0;2</xref>). As these FPG and IRI were both reduced, HOMA-IR was significantly decreased (<xref rid="t0010" ref-type="table">Table&#x000a0;2</xref>). QUICKI showed a trend of reduction by 2.70% (p&#x000a0;=&#x000a0;0.09), and cWBISI was significantly increased (+&#x000a0;20.61%, p&#x000a0;=&#x000a0;0.029) in MS subjects. Upon 75&#x000a0;g-OGTT, FPG and glucose levels at 90&#x000a0;min were significantly lower than those at the non-treatment period (<xref rid="f0010" ref-type="fig">Fig.&#x000a0;2</xref>A). The insulin secreting indices, I.I. and HOMA-&#x003b2; were also evaluated. Although IRI response against glucose load was quite similar to the non-treatment period, I.I. showed a significant decrease in MS subjects (<xref rid="t0010" ref-type="table">Table&#x000a0;2</xref> and <xref rid="f0010" ref-type="fig">Fig.&#x000a0;2</xref>B). HOMA-&#x003b2; was unchanged during the study.</p><p>HbA1c (NGSP) levels showed a trend toward reduction (&#x02212;&#x000a0;0.07&#x000a0;&#x000b1;&#x000a0;0.04%, p&#x000a0;=&#x000a0;0.143) in MS, and this was significantly decreased (&#x02212;&#x000a0;0.49&#x000a0;&#x000b1;&#x000a0;0.06%) from baseline in T2DM. Compared with no treatment period, HbA1c showed a significant reduction by 0.43% (p&#x000a0;=&#x000a0;0.009). The glucose levels at 0, 120 and 300&#x000a0;min on meal tolerance test were significantly lower (0&#x000a0;min; 115.5 vs 108.7&#x000a0;mg/dL, p&#x000a0;=&#x000a0;0.039. 120&#x000a0;min; 251.2 vs 225.4&#x000a0;mg/dL, p&#x000a0;=&#x000a0;0.048. 300&#x000a0;min; 171.8 vs 130.1&#x000a0;mg/dL, p&#x000a0;=&#x000a0;0.041. <xref rid="f0010" ref-type="fig">Fig.&#x000a0;2</xref>C) in T2DM. The proportion of patients who achieved the HbA1c goal of less than 7.0% was 52.5% in the MES&#x000a0;+&#x000a0;HS-treated period in contrast to 15.0% in the untreated period (<xref rid="f0010" ref-type="fig">Fig.&#x000a0;2</xref>D). Higher pre-HbA1c indicated greater reductions upon MES&#x000a0;+&#x000a0;HS treatment (HbA1c 5.9&#x02013;6.4%: &#x02212;&#x000a0;0.15%, 6.5&#x02013;7.5%: &#x02212;&#x000a0;0.42%, 7.6&#x02013;10.0%: &#x02212;&#x000a0;0.72%. <xref rid="f0010" ref-type="fig">Fig.&#x000a0;2</xref>E)</p></sec><sec id="s0085"><label>3.5</label><title>Inflammatory Cytokines and Adipokines</title><p>Visceral adiposity influences the production of inflammatory cytokines and adipokines. High sensitivity CRP significantly decreased by 53.85% in MS (p&#x000a0;=&#x000a0;0.025) and by 4.54% in T2DM (p&#x000a0;=&#x000a0;0.047) following MES&#x000a0;+&#x000a0;HS treatment. Adiponectin increased by 8.36% and 6.63% in MS and T2DM, respectively. Leptin tended to decrease by 8.89% in MS, and displayed a significant reduction by 10.61% in T2DM. TNF-&#x003b1; dropped by 8.97% and 21.60% in MS and T2DM, respectively. Interleukin-6 showed a significant reduction in MS (&#x02212;&#x000a0;28.33%), but not in T2DM (&#x02212;&#x000a0;2.50%).</p></sec><sec id="s0090"><label>3.6</label><title>Other Metabolic Benefits</title><p>To evaluate liver fat accumulation non-invasively, the AST/ALT ratio and liver/spleen attenuation (L/S) ratio were calculated. In parallel with the reduction of visceral adiposity by MES&#x000a0;+&#x000a0;HS treatment, the AST/ALT ratio increased with the treatment (<xref rid="t0015" ref-type="table">Table&#x000a0;3</xref>). The L/S ratio showed a similar alteration (<xref rid="t0015" ref-type="table">Table&#x000a0;3</xref>).</p><p>LDL-cholesterol was decreased as shown in <xref rid="t0015" ref-type="table">Table&#x000a0;3</xref>. HDL-C was increased only in T2DM subjects (<xref rid="t0015" ref-type="table">Table&#x000a0;3</xref>). Although BUN was not changed, serum creatinine (Cre) was slightly but significantly decreased in T2DM. Urinary excretion of albumin adjusted by urinary Cre was also reduced in T2DM.</p></sec><sec id="s0095"><label>3.7</label><title>Inflammatory Characteristics of Monocytes</title><p>To identify the effects of MES&#x000a0;+&#x000a0;HS on the inflammatory milieu in vivo, CD14 positive circulating monocytes were isolated, and levels of cytokine expression were examined both in MS and T2DM. After 4&#x000a0;weeks of MES&#x000a0;+&#x000a0;HS treatment, HSP72 protein levels in monocytes were significantly increased by 34.5% compared to baseline in MS (<xref rid="f0015" ref-type="fig">Fig.&#x000a0;3</xref>A and B. p&#x000a0;&#x0003c;&#x000a0;0.001), and by 41.7% in T2DM (<xref rid="f0020" ref-type="fig">Fig.&#x000a0;4</xref>A and B. p&#x000a0;&#x0003c;&#x000a0;0.001). Phosphorylation of AMP-kinase (AMPK) was also increased by 79.9% in MS (<xref rid="f0015" ref-type="fig">Fig.&#x000a0;3</xref>A and B. p&#x000a0;=&#x000a0;0.0002), and by 63.2% in T2DM (<xref rid="f0020" ref-type="fig">Fig.&#x000a0;4</xref>A and B. p&#x000a0;=&#x000a0;0.017). Phospho-c-jun N-terminal kinase (p-JNK) was attenuated by 42.1% in 56 KDa (p&#x000a0;&#x0003c;&#x000a0;0.001) and by 52.6% in 45 KDa (p&#x000a0;&#x0003c;&#x000a0;0.001) subunits in MS (<xref rid="f0015" ref-type="fig">Fig.&#x000a0;3</xref>A and B), and by 57.8% (p&#x000a0;=&#x000a0;0.0002) and by 32.3% (p&#x000a0;=&#x000a0;0.048), respectively in T2DM (<xref rid="f0020" ref-type="fig">Fig.&#x000a0;4</xref>A and B). LPS-stimulated NF-&#x003ba;B p65 subunit nuclear translocation, visualized by immunofluorescence, was attenuated in both MS and T2DM subjects after MES&#x000a0;+&#x000a0;HS treatment (<xref rid="f0015" ref-type="fig">Figs.&#x000a0;3</xref>C and <xref rid="f0020" ref-type="fig">4</xref>C). In MS, mRNA expression for CRP, IL-6, NF-&#x003ba;B and TNF-&#x003b1; showed reductions by 28.0% (p&#x000a0;=&#x000a0;0.006), 7.5% (p&#x000a0;=&#x000a0;0.36), 22.7% (p&#x000a0;=&#x000a0;0.044) and 23.3% (p&#x000a0;=&#x000a0;0.030), respectively (<xref rid="f0015" ref-type="fig">Fig.&#x000a0;3</xref>D). In T2DM, mRNA expression of CRP, IL-6, NF-&#x003ba;B and TNF-&#x003b1; was decreased by 24.9% (p&#x000a0;=&#x000a0;0.046), 15.1% (p&#x000a0;=&#x000a0;0.06), 17.7% (p&#x000a0;=&#x000a0;0.011) and 33.5% (p&#x000a0;=&#x000a0;0.025), respectively (<xref rid="f0020" ref-type="fig">Fig.&#x000a0;4</xref>D).</p></sec></sec><sec id="s0100"><label>4</label><title>Discussion</title><p>Obesity due to sedentary lifestyle and/or unbalanced diet causes lifestyle-related diseases such as MS or T2DM, characterized by elevated blood glucose, often accompanied by dyslipidemia and hypertension with chronic inflammation resulting from an over-accumulation of visceral fat (<xref rid="bb0010" ref-type="bibr">Alberti et al., 2005</xref>). In this study, we demonstrated that MES&#x000a0;+&#x000a0;HS, which activates the heat shock response (<xref rid="bb0025" ref-type="bibr">Morino et al., 2008a</xref>, <xref rid="bb0045" ref-type="bibr">Kondo et al., 2012</xref>), significantly improved visceral adiposity, insulin resistance, glucose homeostasis and cytokine levels in males with MS or T2DM.</p><p>MES&#x000a0;+&#x000a0;HS treatment significantly improved insulin resistance in subjects with MS or T2DM. Particularly in T2DM, we have identified significant improvements in HbA1c, FPG, postprandial glucose excursion and insulin resistance. More than half of the T2DM subjects achieved HbA1c less than 7.0%.</p><p>Insulin resistance is a central feature of these MS and T2DM, and impaired insulin signaling may be associated with attenuated HSP72 production (<xref rid="bb0085" ref-type="bibr">Bruce et al., 2003</xref>, <xref rid="bb0090" ref-type="bibr">Kurucz et al., 2002</xref>). HSP72 is a cytoplasmic molecular chaperone, which is induced by several stimuli such as heat shock, viral infection or heavy metal contamination etc., and protects cells from apoptosis or cellular dysfunction caused by such cell stresses (<xref rid="bb0095" ref-type="bibr">Hooper et al., 2014</xref>).</p><p>HSP72 transcription is regulated by insulin signaling target, glycogen synthase kinase (GSK)-3&#x003b2;.</p><p>Phosphorylation of GSK-3&#x003b2; blocks the GSK-3 inactivation of HSF-1 and thereby increases activity of HSF-1 (<xref rid="bb0095" ref-type="bibr">Hooper et al., 2014</xref>).</p><p>It is known that HSP72 inhibits JNK activity, resulting in the attenuation of inflammatory signals. However, chronic activation of stress signals down-regulates HSP72 levels through insulin resistance, and results in further activation of inflammatory milieu. This vicious metabolic cycle characterized by systemic inflammation, impaired insulin signaling and attenuated HSR is proposed to occur in MS and T2DM (<xref rid="bb0100" ref-type="bibr">Hooper, 2009</xref>). These components could be improved by the activation of HSR. Indeed, induction of HSP72 by several modalities such as MES&#x000a0;+&#x000a0;HS, whole-body hyperthermia, muscle-specific HSP72 overexpression, and HSP inducers has been shown to improve insulin signaling in mice, monkeys and humans (<xref rid="bb0025" ref-type="bibr">Morino et al., 2008a</xref>, <xref rid="bb0030" ref-type="bibr">Adachi et al., 2010</xref>, <xref rid="bb0035" ref-type="bibr">Chung et al., 2008</xref>, <xref rid="bb0045" ref-type="bibr">Kondo et al., 2012</xref>, <xref rid="bb0050" ref-type="bibr">Kavanagh et al., 2011</xref>, <xref rid="bb0105" ref-type="bibr">Literati-Nagy et al., 2009</xref>).</p><p>The beneficial effects of HSP72 in insulin signaling may be partly explained by the suppression of JNK (<xref rid="bb0035" ref-type="bibr">Chung et al., 2008</xref>). Deletion of JNK1 protects mice from high-fat diet-induced insulin resistance, in part through decreased adiposity. Indeed, suppression of JNK in diabetic mice ameliorates insulin resistance and glucose intolerance (<xref rid="bb0110" ref-type="bibr">Kaneto et al., 2004</xref>). It has also been reported that an HSP72 polymorphism is linked to increased obesity and diabetes risk in humans (<xref rid="bb0115" ref-type="bibr">Zouari Bouassida et al., 2004</xref>). Induction of HSP72 enhances mitochondrial capacity and/or function (<xref rid="bb0035" ref-type="bibr">Chung et al., 2008</xref>, <xref rid="bb0120" ref-type="bibr">Henstridge et al., 2014</xref>), and suppresses JNK activity (<xref rid="bb0025" ref-type="bibr">Morino et al., 2008a</xref>, <xref rid="bb0045" ref-type="bibr">Kondo et al., 2012</xref>). In addition, uncoupling protein-1 mRNA expression in brown adipose tissue was increased in MES&#x000a0;+&#x000a0;HS-treated diabetic animals (<xref rid="bb0025" ref-type="bibr">Morino et al., 2008a</xref>). Moreover, MES&#x000a0;+&#x000a0;HS treatment activates AMPK in mice (<xref rid="bb0045" ref-type="bibr">Kondo et al., 2012</xref>). In fact, AMPK &#x003b1;1 knockouts showed increased visceral adiposity with insulin resistance (<xref rid="bb0125" ref-type="bibr">Zhang et al., 2012</xref>). As we have identified the activation of AMPK in monocytes, this may contribute to reduce visceral adiposity. In addition, testosterone treatment ameliorates metabolic abnormalities, including adipocyte hypertrophy, adipose tissue dysfunction, tissue hypoxia and insulin resistance (<xref rid="bb0130" ref-type="bibr">Maneschi et al., 2012</xref>). Heat treatment activates androgen effect especially in lipid peroxidation, indicating that activation of androgen signal through HSR activation may also participate in the beneficial effects of MES&#x000a0;+&#x000a0;HS. These mechanisms may participate in the reduction of visceral adiposity by MES&#x000a0;+&#x000a0;HS treatment, which need further investigation.</p><p>Increased production of pro-inflammatory cytokines is associated with impaired insulin sensitivity (<xref rid="bb0020" ref-type="bibr">Tamakoshi et al., 2003</xref>). We previously reported that activation of the HSR by MES&#x000a0;+&#x000a0;HS in diabetic mice was associated with metabolic benefits, accompanied by improvements in inflammatory cytokine productions (<xref rid="bb0025" ref-type="bibr">Morino et al., 2008a</xref>). In this study, we observed similar cytokine changes in human subjects with MS and T2DM. Although this may be partly explained by the reduction in visceral adiposity, we also reported significant reductions in CRP and TNF-&#x003b1; levels by MES&#x000a0;+&#x000a0;HS in healthy subjects without any body composition changes (<xref rid="bb0070" ref-type="bibr">Kondo et al., 2010</xref>). These results suggest a possible direct association between HSR activation and suppression of systemic inflammation. High serum CRP levels are associated with reduced HSP72 levels (<xref rid="bb0135" ref-type="bibr">Armutcu et al., 2008</xref>), and are positively regulated by NF-&#x003ba;B, which can be attenuated by HSP72. Indeed, we observed a significant increase in HSP72 with reduction of NF-&#x003ba;B nuclear accumulation in monocytes after MES&#x000a0;+&#x000a0;HS treatment. HSP72 also decreases TNF-&#x003b1; levels by suppression of NF-&#x003ba;B as well. Therefore, induction of HSP72 by MES&#x000a0;+&#x000a0;HS could decrease inflammatory cytokines through suppression of NF-&#x003ba;B activation. It is also possible that an anti-inflammatory effect of MES&#x000a0;+&#x000a0;HS could be achieved by AMPK activation, because AMPK &#x003b1;1 deficiency in macrophages markedly increases the pro-inflammatory status (<xref rid="bb0125" ref-type="bibr">Zhang et al., 2012</xref>). As chronic activation of inflammatory status is associated with atherogenesis, anti-inflammatory effect of MES&#x000a0;+&#x000a0;HS may contribute to limit future vascular complications.</p><p>Because visceral fat produces angiotensinogen and increases sympathetic nervous activity, MS and T2DM are often associated with hypertension. In this regard, reduction in blood pressure as a result of MES&#x000a0;+&#x000a0;HS treatment could be explained, at least in part, by a reduction in visceral adiposity. Recently, it has been shown that heat treatment in high fat-fed mice augmented angiotensin (<xref rid="bb0005" ref-type="bibr">Shichiri et al., 2000</xref>, <xref rid="bb0010" ref-type="bibr">Alberti et al., 2005</xref>, <xref rid="bb0015" ref-type="bibr">Ohman et al., 2009</xref>, <xref rid="bb0020" ref-type="bibr">Tamakoshi et al., 2003</xref>, <xref rid="bb0025" ref-type="bibr">Morino et al., 2008a</xref>, <xref rid="bb0030" ref-type="bibr">Adachi et al., 2010</xref>, <xref rid="bb0035" ref-type="bibr">Chung et al., 2008</xref>), which counteracts against angiotensin II, through Mas receptor/eNOS axis that may improve blood pressure and endothelial dysfunction (<xref rid="bb0140" ref-type="bibr">Karpe and Tikoo, 2014</xref>). Therefore, both reductions in visceral fat and eNOS activation may contribute to ameliorate hypertension upon MES&#x000a0;+&#x000a0;HS treatment.</p><p>Hepatic steatosis is considered to be one of the phenotypes of lifestyle-related diseases. Our results indicate that activation of the HSR by MES&#x000a0;+&#x000a0;HS improved surrogate markers of fatty liver. Although precise interaction between HSR activation and improvement of fatty liver is still unknown, naringin, a bioflavonoid isolated from grapefruit, activates HSP72 and attenuates hepatic steatosis (<xref rid="bb0145" ref-type="bibr">Sharma et al., 2011</xref>). Alternatively, endoplasmic reticulum (ER) stress attenuation by HSR activation may be involved in this process, because HSP72 enhances ER capacity, and hepatic lipid accumulation is correlated with ER stress (<xref rid="bb0150" ref-type="bibr">Gupta et al., 2010</xref>).</p><p>The molecular mechanisms involved in metabolic benefits of MES&#x000a0;+&#x000a0;HS appear to be similar to those observed in exercise, particularly in HSP72 induction and AMPK activation (<xref rid="bb0155" ref-type="bibr">Zhang et al., 2009</xref>). Indeed, 8&#x000a0;weeks of endurance training in diabetic rats increased HSP72 expression (<xref rid="bb0160" ref-type="bibr">Atalay et al., 2004</xref>). It is also proposed that HSR activators share metabolic pathways associated with exercise with activation of AMPK (<xref rid="bb0095" ref-type="bibr">Hooper et al., 2014</xref>).</p><p>Thus, MES&#x000a0;+&#x000a0;HS treatment may mimic exercise training sharing with similar mechanisms and results.</p><sec id="s0105"><label>4.1</label><title>Limitations</title><p>This study was conducted in relatively small number, and the participants were limited to male only in order to preclude menstruation cycle, which may disturb metabolic parameters.</p></sec></sec><sec id="s0110"><label>5</label><title>Conclusion</title><p>MES&#x000a0;+&#x000a0;HS treatment exerts anti-visceral obesity, anti-hypertensive, anti-diabetic and anti-inflammatory effects with no harmfulness, possibly through HSP72 induction and AMPK activation. Moreover, it can also be used in physically handicapped or bed-ridden patients who are unable to follow an exercise regimen. MES&#x000a0;+&#x000a0;HS could be analogous to exercise training in terms of HSP72 induction and AMPK activation, and might confer additional benefits, such as anti-atherogenic effect. HSR activation by physical MES&#x000a0;+&#x000a0;HS system may be an alternative and beneficial therapeutic approach to the treatment of lifestyle-related diseases.</p></sec><sec id="s0115"><title>Conflict of interest</title><p>The authors report no potential conflicts of interest relevant to this article.</p></sec><sec id="s0120"><title>Author contributions</title><p>T.K. designed the study, researched data, contributed to discussion and wrote the manuscript. K.O. and S.Ki. researched data, and contributed to discussion. R.M. and R.G., researched data. M.A.S., S.Ka., M.I., J.K., H.M., and T.M., contributed to the discussion. H.K. reviewed and edited the manuscript. E.A. designed the study, reviewed and edited the manuscript.</p></sec><sec id="s0125"><title>Funding</title><p>This work was supported by Japanese government <funding-source id="gts0010">MEXT KAKENHI</funding-source> (Grants-in-Aid for Scientific Research from Ministry of Education, Culture, Sports, Science and Technology, Japan) 2259098701 to TK, 2339024300 to EA. The sponsor of this study has no role in the study design, data collection, data analysis, data interpretation, or writing of the report.</p></sec></body><back><ref-list><title>References</title><ref id="bb0030"><element-citation publication-type="journal" id="rf0030"><person-group person-group-type="author"><name><surname>Adachi</surname><given-names>H.</given-names></name><name><surname>Kondo</surname><given-names>T.</given-names></name><name><surname>Ogawa</surname><given-names>R.</given-names></name></person-group><article-title>An acylic polyisoprenoid derivative, geranylgeranylacetone protects against visceral adiposity and insulin resistance in high fat fed mice</article-title><source>Am. J. Physiol. Endocrinol. Metab.</source><volume>299</volume><issue>5</issue><year>2010</year><fpage>E764</fpage><lpage>E771</lpage><pub-id pub-id-type="pmid">20716696</pub-id></element-citation></ref><ref id="bb0010"><element-citation publication-type="journal" id="rf0010"><person-group person-group-type="author"><name><surname>Alberti</surname><given-names>K.G.</given-names></name><name><surname>Zimmet</surname><given-names>P.</given-names></name><name><surname>Shaw</surname><given-names>J.</given-names></name></person-group><article-title>The metabolic syndrome &#x02014; a new worldwide definition</article-title><source>Lancet</source><volume>366</volume><issue>9491</issue><year>2005</year><fpage>1059</fpage><lpage>1062</lpage><pub-id pub-id-type="pmid">16182882</pub-id></element-citation></ref><ref id="bb0135"><element-citation publication-type="journal" id="rf0110"><person-group person-group-type="author"><name><surname>Armutcu</surname><given-names>F.</given-names></name><name><surname>Ataymen</surname><given-names>M.</given-names></name><name><surname>Atmaca</surname><given-names>H.</given-names></name><name><surname>Gurel</surname><given-names>A.</given-names></name></person-group><article-title>Oxidative stress markers, C-reactive protein and heat shock protein 70 levels in subjects with metabolic syndrome</article-title><source>Clin. Chem. Lab. Med.</source><volume>46</volume><issue>6</issue><year>2008</year><fpage>785</fpage><lpage>790</lpage><pub-id pub-id-type="pmid">18601599</pub-id></element-citation></ref><ref id="bb0160"><element-citation publication-type="journal" id="rf0135"><person-group person-group-type="author"><name><surname>Atalay</surname><given-names>M.</given-names></name><name><surname>Oksala</surname><given-names>N.K.</given-names></name><name><surname>Laaksonen</surname><given-names>D.E.</given-names></name></person-group><article-title>Exercise training modulates heat shock protein response in diabetic rats</article-title><source>J. Appl. Physiol.</source><volume>97</volume><issue>2</issue><year>2004</year><fpage>605</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">15075301</pub-id></element-citation></ref><ref id="bb0085"><element-citation publication-type="journal" id="rf0065"><person-group person-group-type="author"><name><surname>Bruce</surname><given-names>C.R.</given-names></name><name><surname>Carey</surname><given-names>A.L.</given-names></name><name><surname>Hawley</surname><given-names>J.A.</given-names></name><name><surname>Febbraio</surname><given-names>M.A.</given-names></name></person-group><article-title>Intramuscular heat shock protein 72 and heme oxygenase-1 mRNA are reduced in patients with type 2 diabetes: evidence that insulin resistance is associated with a disturbed antioxidant defense mechanism</article-title><source>Diabetes</source><volume>52</volume><issue>9</issue><year>2003</year><fpage>2338</fpage><lpage>2345</lpage><pub-id pub-id-type="pmid">12941774</pub-id></element-citation></ref><ref id="bb0035"><element-citation publication-type="journal" id="rf0035"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>J.</given-names></name><name><surname>Nguyen</surname><given-names>A.K.</given-names></name><name><surname>Henstridge</surname><given-names>D.C.</given-names></name></person-group><article-title>HSP72 protects against obesity-induced insulin resistance</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>105</volume><issue>5</issue><year>2008</year><fpage>1739</fpage><lpage>1744</lpage><pub-id pub-id-type="pmid">18223156</pub-id></element-citation></ref><ref id="bb0150"><element-citation publication-type="journal" id="rf0125"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S.</given-names></name><name><surname>Deepti</surname><given-names>A.</given-names></name><name><surname>Deegan</surname><given-names>S.</given-names></name><name><surname>Lisbona</surname><given-names>F.</given-names></name><name><surname>Hetz</surname><given-names>C.</given-names></name><name><surname>Samali</surname><given-names>A.</given-names></name></person-group><article-title>HSP72 protects cells from ER stress-induced apoptosis via enhancement of IRE1alpha-XBP1 signaling through a physical interaction</article-title><source>PLoS Biol.</source><volume>8</volume><issue>7</issue><year>2010</year><fpage>e1000410</fpage><pub-id pub-id-type="pmid">20625543</pub-id></element-citation></ref><ref id="bb0040"><element-citation publication-type="journal" id="rf0040"><person-group person-group-type="author"><name><surname>Gupte</surname><given-names>A.A.</given-names></name><name><surname>Bomhoff</surname><given-names>G.L.</given-names></name><name><surname>Swerdlow</surname><given-names>R.H.</given-names></name><name><surname>Geiger</surname><given-names>P.C.</given-names></name></person-group><article-title>Heat treatment improves glucose tolerance and prevents skeletal muscle insulin resistance in rats fed a high-fat diet</article-title><source>Diabetes</source><volume>58</volume><issue>3</issue><year>2009</year><fpage>567</fpage><lpage>578</lpage><pub-id pub-id-type="pmid">19073766</pub-id></element-citation></ref><ref id="bb0120"><element-citation publication-type="journal" id="rf0100"><person-group person-group-type="author"><name><surname>Henstridge</surname><given-names>D.C.</given-names></name><name><surname>Bruce</surname><given-names>C.R.</given-names></name><name><surname>Drew</surname><given-names>B.G.</given-names></name></person-group><article-title>Activating HSP72 in rodent skeletal muscle increases mitochondrial number and oxidative capacity and decreases insulin resistance</article-title><source>Diabetes</source><volume>63</volume><issue>6</issue><year>2014</year><fpage>1881</fpage><lpage>1894</lpage><pub-id pub-id-type="pmid">24430435</pub-id></element-citation></ref><ref id="bb0100"><element-citation publication-type="journal" id="rf0080"><person-group person-group-type="author"><name><surname>Hooper</surname><given-names>P.L.</given-names></name></person-group><article-title>Inflammation, heat shock proteins, and type 2 diabetes</article-title><source>Cell Stress Chaperones</source><volume>14</volume><issue>2</issue><year>2009</year><fpage>113</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">18720028</pub-id></element-citation></ref><ref id="bb0095"><element-citation publication-type="journal" id="rf0075"><person-group person-group-type="author"><name><surname>Hooper</surname><given-names>P.L.</given-names></name><name><surname>Balogh</surname><given-names>G.</given-names></name><name><surname>Rivas</surname><given-names>E.</given-names></name><name><surname>Kavanagh</surname><given-names>K.</given-names></name><name><surname>Vigh</surname><given-names>L.</given-names></name></person-group><article-title>The importance of the cellular stress response in the pathogenesis and treatment of type 2 diabetes</article-title><source>Cell Stress Chaperones</source><volume>19</volume><issue>4</issue><year>2014</year><fpage>447</fpage><lpage>464</lpage><pub-id pub-id-type="pmid">24523032</pub-id></element-citation></ref><ref id="bb0110"><element-citation publication-type="journal" id="rf0090"><person-group person-group-type="author"><name><surname>Kaneto</surname><given-names>H.</given-names></name><name><surname>Nakatani</surname><given-names>Y.</given-names></name><name><surname>Miyatsuka</surname><given-names>T.</given-names></name></person-group><article-title>Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide</article-title><source>Nat. Med.</source><volume>10</volume><issue>10</issue><year>2004</year><fpage>1128</fpage><lpage>1132</lpage><pub-id pub-id-type="pmid">15448687</pub-id></element-citation></ref><ref id="bb0140"><element-citation publication-type="journal" id="rf0115"><person-group person-group-type="author"><name><surname>Karpe</surname><given-names>P.A.</given-names></name><name><surname>Tikoo</surname><given-names>K.</given-names></name></person-group><article-title>Heat shock prevents insulin resistance-induced vascular complications by augmenting angiotensin-(1&#x02013;7) signaling</article-title><source>Diabetes</source><volume>63</volume><issue>3</issue><year>2014</year><fpage>1124</fpage><lpage>1139</lpage><pub-id pub-id-type="pmid">24270982</pub-id></element-citation></ref><ref id="bb0050"><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name><surname>Kavanagh</surname><given-names>K.</given-names></name><name><surname>Flynn</surname><given-names>D.M.</given-names></name><name><surname>Jenkins</surname><given-names>K.A.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Wagner</surname><given-names>J.D.</given-names></name></person-group><article-title>Restoring HSP70 deficiencies improves glucose tolerance in diabetic monkeys</article-title><source>Am. J. Physiol. Endocrinol. Metab.</source><volume>300</volume><issue>5</issue><year>2011</year><fpage>E894</fpage><lpage>E901</lpage><pub-id pub-id-type="pmid">21325107</pub-id></element-citation></ref><ref id="bb0070"><element-citation publication-type="journal" id="rf0140"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>T.</given-names></name><name><surname>Sasaki</surname><given-names>K.</given-names></name><name><surname>Adachi</surname><given-names>H.</given-names></name></person-group><article-title>Heat shock treatment with mild electrical stimulation safely reduced inflammatory markers in healthy male subjects</article-title><source>Obes. Res. Clin. Pract.</source><volume>4</volume><issue>2</issue><year>2010</year><fpage>e101</fpage><lpage>e109</lpage></element-citation></ref><ref id="bb0045"><element-citation publication-type="journal" id="rf0045"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>T.</given-names></name><name><surname>Sasaki</surname><given-names>K.</given-names></name><name><surname>Matsuyama</surname><given-names>R.</given-names></name></person-group><article-title>Hyperthermia with mild electrical stimulation protects pancreatic beta-cells from cell stresses and apoptosis</article-title><source>Diabetes</source><volume>61</volume><issue>4</issue><year>2012</year><fpage>838</fpage><lpage>847</lpage><pub-id pub-id-type="pmid">22362176</pub-id></element-citation></ref><ref id="bb0090"><element-citation publication-type="journal" id="rf0070"><person-group person-group-type="author"><name><surname>Kurucz</surname><given-names>I.</given-names></name><name><surname>Morva</surname><given-names>A.</given-names></name><name><surname>Vaag</surname><given-names>A.</given-names></name></person-group><article-title>Decreased expression of heat shock protein 72 in skeletal muscle of patients with type 2 diabetes correlates with insulin resistance</article-title><source>Diabetes</source><volume>51</volume><issue>4</issue><year>2002</year><fpage>1102</fpage><lpage>1109</lpage><pub-id pub-id-type="pmid">11916932</pub-id></element-citation></ref><ref id="bb0105"><element-citation publication-type="journal" id="rf0085"><person-group person-group-type="author"><name><surname>Literati-Nagy</surname><given-names>B.</given-names></name><name><surname>Kulcsar</surname><given-names>E.</given-names></name><name><surname>Literati-Nagy</surname><given-names>Z.</given-names></name></person-group><article-title>Improvement of insulin sensitivity by a novel drug, BGP-15, in insulin-resistant patients: a proof of concept randomized double-blind clinical trial</article-title><source>Horm. Metab. Res.</source><volume>41</volume><issue>5</issue><year>2009</year><fpage>374</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">19214941</pub-id></element-citation></ref><ref id="bb0130"><element-citation publication-type="journal" id="rf0105"><person-group person-group-type="author"><name><surname>Maneschi</surname><given-names>E.</given-names></name><name><surname>Morelli</surname><given-names>A.</given-names></name><name><surname>Filippi</surname><given-names>S.</given-names></name></person-group><article-title>Testosterone treatment improves metabolic syndrome-induced adipose tissue derangements</article-title><source>J. Endocrinol.</source><volume>215</volume><issue>3</issue><year>2012</year><fpage>347</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">23045189</pub-id></element-citation></ref><ref id="bb0025"><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name><surname>Morino</surname><given-names>S.</given-names></name><name><surname>Kondo</surname><given-names>T.</given-names></name><name><surname>Sasaki</surname><given-names>K.</given-names></name></person-group><article-title>Mild electrical stimulation with heat shock ameliorates insulin resistance via enhanced insulin signaling</article-title><source>PLoS One</source><volume>3</volume><issue>12</issue><year>2008</year><fpage>e4068</fpage><pub-id pub-id-type="pmid">19114996</pub-id></element-citation></ref><ref id="bb0055"><element-citation publication-type="journal" id="rf0055"><person-group person-group-type="author"><name><surname>Morino</surname><given-names>S.</given-names></name><name><surname>Suico</surname><given-names>M.A.</given-names></name><name><surname>Kondo</surname><given-names>T.</given-names></name></person-group><article-title>Mild electrical stimulation increases ubiquitinated proteins and Hsp72 in A549 cells via attenuation of proteasomal degradation</article-title><source>J. Pharmacol. Sci.</source><volume>108</volume><issue>2</issue><year>2008</year><fpage>222</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">18845908</pub-id></element-citation></ref><ref id="bb0065"><element-citation publication-type="journal" id="rf0145"><person-group person-group-type="author"><name><surname>Morino-Koga</surname><given-names>S.</given-names></name><name><surname>Yano</surname><given-names>S.</given-names></name><name><surname>Kondo</surname><given-names>T.</given-names></name></person-group><article-title>Insulin receptor activation through its accumulation in lipid rafts by mild electrical stress</article-title><source>J. Cell. Physiol.</source><volume>228</volume><issue>2</issue><year>2013</year><fpage>439</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">22740366</pub-id></element-citation></ref><ref id="bb0015"><element-citation publication-type="journal" id="rf0015"><person-group person-group-type="author"><name><surname>Ohman</surname><given-names>M.K.</given-names></name><name><surname>Wright</surname><given-names>A.P.</given-names></name><name><surname>Wickenheiser</surname><given-names>K.J.</given-names></name><name><surname>Luo</surname><given-names>W.</given-names></name><name><surname>Eitzman</surname><given-names>D.T.</given-names></name></person-group><article-title>Visceral adipose tissue and atherosclerosis</article-title><source>Curr. Vasc. Pharmacol.</source><volume>7</volume><issue>2</issue><year>2009</year><fpage>169</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">19356000</pub-id></element-citation></ref><ref id="bb0145"><element-citation publication-type="journal" id="rf0120"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A.K.</given-names></name><name><surname>Bharti</surname><given-names>S.</given-names></name><name><surname>Ojha</surname><given-names>S.</given-names></name></person-group><article-title>Up-regulation of PPARgamma, heat shock protein-27 and -72 by naringin attenuates insulin resistance, beta-cell dysfunction, hepatic steatosis and kidney damage in a rat model of type 2 diabetes</article-title><source>Br. J. Nutr.</source><volume>106</volume><issue>11</issue><year>2011</year><fpage>1713</fpage><lpage>1723</lpage><pub-id pub-id-type="pmid">21736771</pub-id></element-citation></ref><ref id="bb0005"><element-citation publication-type="journal" id="rf0005"><person-group person-group-type="author"><name><surname>Shichiri</surname><given-names>M.</given-names></name><name><surname>Kishikawa</surname><given-names>H.</given-names></name><name><surname>Ohkubo</surname><given-names>Y.</given-names></name><name><surname>Wake</surname><given-names>N.</given-names></name></person-group><article-title>Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients</article-title><source>Diabetes Care</source><volume>23</volume><issue>Suppl. 2</issue><year>2000</year><fpage>B21</fpage><lpage>B29</lpage><pub-id pub-id-type="pmid">10860187</pub-id></element-citation></ref><ref id="bb0020"><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name><surname>Tamakoshi</surname><given-names>K.</given-names></name><name><surname>Yatsuya</surname><given-names>H.</given-names></name><name><surname>Kondo</surname><given-names>T.</given-names></name></person-group><article-title>The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state</article-title><source>Int. J. Obes. Relat. Metab. Disord.</source><volume>27</volume><issue>4</issue><year>2003</year><fpage>443</fpage><lpage>449</lpage><pub-id pub-id-type="pmid">12664077</pub-id></element-citation></ref><ref id="bb0080"><element-citation publication-type="journal" id="rf0150"><person-group person-group-type="author"><name><surname>Yamashiro</surname><given-names>T.</given-names></name><name><surname>Nishikawa</surname><given-names>T.</given-names></name><name><surname>Isami</surname><given-names>S.</given-names></name></person-group><article-title>The effect of group-based lifestyle interventions on risk factors and insulin resistance in subjects at risk for metabolic syndrome: the Tabaruzaka Study 1</article-title><source>Diabetes Obes. Metab.</source><volume>12</volume><issue>9</issue><year>2010</year><fpage>790</fpage><lpage>797</lpage><pub-id pub-id-type="pmid">20649631</pub-id></element-citation></ref><ref id="bb0060"><element-citation publication-type="journal" id="rf0060"><person-group person-group-type="author"><name><surname>Yano</surname><given-names>S.</given-names></name><name><surname>Morino-Koga</surname><given-names>S.</given-names></name><name><surname>Kondo</surname><given-names>T.</given-names></name></person-group><article-title>Glucose uptake in rat skeletal muscle L6 cells is increased by low-intensity electrical current through the activation of the phosphatidylinositol-3-OH kinase (PI-3K)/Akt pathway</article-title><source>J. Pharmacol. Sci.</source><volume>115</volume><issue>1</issue><year>2010</year><fpage>94</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">21178318</pub-id></element-citation></ref><ref id="bb0155"><element-citation publication-type="journal" id="rf0130"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B.B.</given-names></name><name><surname>Zhou</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name></person-group><article-title>AMPK: an emerging drug target for diabetes and the metabolic syndrome</article-title><source>Cell Metab.</source><volume>9</volume><issue>5</issue><year>2009</year><fpage>407</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">19416711</pub-id></element-citation></ref><ref id="bb0125"><element-citation publication-type="journal" id="rf0155"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>AMP-activated protein kinase alpha1 protects against diet-induced insulin resistance and obesity</article-title><source>Diabetes</source><volume>61</volume><issue>12</issue><year>2012</year><fpage>3114</fpage><lpage>3125</lpage><pub-id pub-id-type="pmid">22829451</pub-id></element-citation></ref><ref id="bb0115"><element-citation publication-type="journal" id="rf0095"><person-group person-group-type="author"><name><surname>Zouari Bouassida</surname><given-names>K.</given-names></name><name><surname>Chouchane</surname><given-names>L.</given-names></name><name><surname>Jellouli</surname><given-names>K.</given-names></name></person-group><article-title>Polymorphism of stress protein HSP70-2 gene in Tunisians: susceptibility implications in type 2 diabetes and obesity</article-title><source>Diabetes Metab.</source><volume>30</volume><issue>2</issue><year>2004</year><fpage>175</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">15223990</pub-id></element-citation></ref></ref-list><sec id="s0130" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p><supplementary-material content-type="local-data" id="ec0005"><caption><p>Supplemental information. Original protocol, final protocol and summary of changes for these trials are indicated.</p></caption><media xlink:href="mmc1.docx"/></supplementary-material></p></sec><ack id="ac0005"><title>Acknowledgments</title><p>We appreciate the helpful advice and assistance of Mr. Kenshi Ichinose and Miki Sato in our laboratory. The device used for MES&#x000a0;+&#x000a0;HS treatment was kindly provided by the Tsuchiya Rubber Co. Ltd. (Kumamoto, Japan).</p></ack><fn-group><fn id="s0135" fn-type="supplementary-material"><label>Appendix A</label><p>Supplementary data to this article can be found online at <ext-link ext-link-type="doi" xlink:href="10.1016/j.ebiom.2014.11.001" id="ir0005">http://dx.doi.org/10.1016/j.ebiom.2014.11.001</ext-link>.</p></fn></fn-group></back><floats-group><fig id="f0005"><label>Fig.&#x000a0;1</label><caption><p>Flowchart of study subjects.</p></caption><graphic xlink:href="gr1"/></fig><fig id="f0010"><label>Fig.&#x000a0;2</label><caption><p>Glucose homeostasis in MES&#x000a0;+&#x000a0;HS-treated MS or T2DM subjects. (A) Glucose excursions on 75&#x000a0;g oral glucose tolerance test (OGTT) in MS subjects (n&#x000a0;=&#x000a0;40) after no treatment (open diamonds with solid line) or MES&#x000a0;+&#x000a0;HS treatment (closed squares with dotted line) period. (B) Serum insulin response on 75&#x000a0;g OGTT in MS after no treatment or MES&#x000a0;+&#x000a0;HS treatment period. (C) Glucose excursions on 592&#x000a0;kcal of meal tolerance test (MTT) in T2DM patients (n&#x000a0;=&#x000a0;40) after no treatment or MES&#x000a0;+&#x000a0;HS treatment period. (D) The ratio of HbA1c less than 7.0% in T2DM patients without MES&#x000a0;+&#x000a0;HS (MES&#x000a0;+&#x000a0;HS(&#x02212;)) or with MES&#x000a0;+&#x000a0;HS treatment period (MES&#x000a0;+&#x000a0;HS(+)). (E) Reductions in HbA1c sorted by pre-HbA1c levels upon MES&#x000a0;+&#x000a0;HS treatment. Sequential changes were analyzed by repeated-measures ANOVA, and the differences at each time point were analyzed by unpaired <italic>t</italic>-test. *p&#x000a0;&#x0003c;&#x000a0;0.05, **p&#x000a0;&#x0003c;&#x000a0;0.01.</p></caption><graphic xlink:href="gr2"/></fig><fig id="f0015"><label>Fig.&#x000a0;3</label><caption><p>Inflammatory characteristics in CD14 positive monocytes in MS subjects. Ten MS subjects were selected, and 4&#x000a0;weeks of MES&#x000a0;+&#x000a0;HS treatment was performed. Before and after the MES&#x000a0;+&#x000a0;HS treatment period, blood sampling was performed on a fasted state. Circulating monocytes were isolated, then HSP72 protein, p-AMPK, p-JNK and actin were determined by Western blot analysis. Representative results are shown in A. The relative intensity calculated using actin is shown in B. (C) Isolated monocytes were subjected to immunofluorescent staining after LPS stimulation using antibodies against NF-&#x003ba;B p65 (red) and CD14 (green). Representative results are shown under low (upper panels) or high (lower panels) magnifications. (D) Isolated monocytes after LPS stimulation were subjected to mRNA measurements of CRP, IL-6, NF-&#x003ba;B and TNF-&#x003b1;. Averages of each mRNA level with or without MES&#x000a0;+&#x000a0;HS treatment are shown. *p&#x000a0;&#x0003c;&#x000a0;0.05, **p&#x000a0;&#x0003c;&#x000a0;0.01.</p></caption><graphic xlink:href="gr3"/></fig><fig id="f0020"><label>Fig.&#x000a0;4</label><caption><p>Inflammatory characteristics in CD14 positive monocytes in T2DM patients. Ten T2DM patients were selected, and 4&#x000a0;weeks of MES&#x000a0;+&#x000a0;HS treatment was performed. Before and after the MES&#x000a0;+&#x000a0;HS treatment period, blood sampling was performed on fasted state. Circulating monocytes were isolated, then HSP72 protein, p-AMPK, p-JNK and actin were determined by Western blot analysis. Representative results are shown in A. The relative intensity calculated using actin is shown in B. (C) Isolated monocytes were subjected to immunofluorescent staining after LPS stimulation using antibodies against NF-&#x003ba;B p65 (red) and CD14 (green). Representative results are shown under low (upper panels) or high (lower panels) magnifications. (D) Isolated monocytes after LPS stimulation were subjected to mRNA measurements of CRP, IL-6, NF-&#x003ba;B and TNF-&#x003b1;. Averages of each mRNA level with or without MES&#x000a0;+&#x000a0;HS treatment are shown. *p&#x000a0;&#x0003c;&#x000a0;0.05, **p&#x000a0;&#x0003c;&#x000a0;0.01.</p></caption><graphic xlink:href="gr4"/></fig><table-wrap id="t0005" position="float"><label>Table&#x000a0;1</label><caption><p>The subjects&#x02019; pre-clinical and biological characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Background characteristics of the subjects</th><th colspan="3" align="left">Metabolic syndrome<hr/></th><th colspan="3" align="left">Type 2 diabetes mellitus<hr/></th></tr><tr><th align="left">Group I</th><th align="left">Group II</th><th align="left">p value</th><th align="left">Group I</th><th align="left">Group II</th><th align="left">p value</th></tr></thead><tbody><tr><td align="left">Male/females</td><td align="left">20/0</td><td align="left">20/0</td><td/><td align="left">20/0</td><td align="left">20/0</td><td/></tr><tr><td align="left">Age (years)</td><td align="left">53.5&#x000a0;&#x000b1;&#x000a0;1.5</td><td align="left">51.3&#x000a0;&#x000b1;&#x000a0;1.6</td><td align="left">0.332</td><td align="left">64.6&#x000a0;&#x000b1;&#x000a0;2.6</td><td align="left">71.9&#x000a0;&#x000b1;&#x000a0;2.6</td><td align="left">0.095</td></tr><tr><td align="left">Body mass index (kg/m<sup>2</sup>)</td><td align="left">26.1&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="left">27.6&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="left">0.093</td><td align="left">28.4&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="left">27.4&#x000a0;&#x000b1;&#x000a0;1.3</td><td align="left">0.486</td></tr><tr><td align="left">% body fat</td><td align="left">26.7&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="left">26.4&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="left">0.890</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Waist circumference (cm)</td><td align="left">92.8&#x000a0;&#x000b1;&#x000a0;l.l</td><td align="left">95.6&#x000a0;&#x000b1;&#x000a0;1.5</td><td align="left">0.120</td><td align="left">98.0&#x000a0;&#x000b1;&#x000a0;2.4</td><td align="left">97.7&#x000a0;&#x000b1;&#x000a0;3.2</td><td align="left">0.867</td></tr><tr><td align="left">Vsiceral fat area (cm<sup>2</sup>)</td><td align="left">147.1&#x000a0;&#x000b1;&#x000a0;6.8</td><td align="left">149.8&#x000a0;&#x000b1;&#x000a0;10.9</td><td align="left">0.774</td><td align="left">189.0&#x000a0;&#x000b1;&#x000a0;11.8</td><td align="left">184.4&#x000a0;&#x000b1;&#x000a0;16.1</td><td align="left">0.774</td></tr><tr><td align="left">Subcutaneous fat area (cm<sup>2</sup>)</td><td align="left">183.5&#x000a0;&#x000b1;&#x000a0;13.1</td><td align="left">200.4&#x000a0;&#x000b1;&#x000a0;13.1</td><td align="left">0.838</td><td align="left">152.7&#x000a0;&#x000b1;&#x000a0;9.2</td><td align="left">169.3&#x000a0;&#x000b1;&#x000a0;20.1</td><td align="left">0.521</td></tr><tr><td align="left">Systolic blood pressure (mm&#x000a0;Hg)</td><td align="left">136.8&#x000a0;&#x000b1;&#x000a0;3.3</td><td align="left">133.9&#x000a0;&#x000b1;&#x000a0;2.6</td><td align="left">0.386</td><td align="left">138.6&#x000a0;&#x000b1;&#x000a0;3.4</td><td align="left">148.1&#x000a0;&#x000b1;&#x000a0;5.4</td><td align="left">0.205</td></tr><tr><td align="left">Diastolic blood pressure (mm&#x000a0;Hg)</td><td align="left">86.6&#x000a0;&#x000b1;&#x000a0;2.4</td><td align="left">84.8&#x000a0;&#x000b1;&#x000a0;2.3</td><td align="left">0.588</td><td align="left">75.2&#x000a0;&#x000b1;&#x000a0;2.3</td><td align="left">74.6&#x000a0;&#x000b1;&#x000a0;2.8</td><td align="left">0.814</td></tr><tr><td align="left">Heart rate (beats/min)</td><td align="left">69.2&#x000a0;&#x000b1;&#x000a0;2.1</td><td align="left">68.7&#x000a0;&#x000b1;&#x000a0;1.6</td><td align="left">0.862</td><td align="left">66.7&#x000a0;&#x000b1;&#x000a0;2.4</td><td align="left">70.4&#x000a0;&#x000b1;&#x000a0;2.3</td><td align="left">0.682</td></tr><tr><td align="left">Current smoking (yes/no)</td><td align="left">7/13</td><td align="left">8/12</td><td align="left">N.S.</td><td align="left">6/13</td><td align="left">4/12</td><td align="left">N.S.</td></tr><tr><td align="left">Fasting plasma glucose (mg/dL)</td><td align="left">107.7&#x000a0;&#x000b1;&#x000a0;2.7</td><td align="left">104.7&#x000a0;&#x000b1;&#x000a0;2.9</td><td align="left">0.457</td><td align="left">158.5&#x000a0;&#x000b1;&#x000a0;9.2</td><td align="left">137.7&#x000a0;&#x000b1;&#x000a0;10.6</td><td align="left">0.153</td></tr><tr><td align="left">Fasting insulin (mIU/mL)</td><td align="left">10.0&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="left">12.9&#x000a0;&#x000b1;&#x000a0;1.6</td><td align="left">0.141</td><td align="left">14.5&#x000a0;&#x000b1;&#x000a0;2.8</td><td align="left">14.5&#x000a0;&#x000b1;&#x000a0;3.3</td><td align="left">0.933</td></tr><tr><td align="left">HOMA-IR</td><td align="left">2.61&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="left">3.36&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="left">0.146</td><td align="left">6.03&#x000a0;&#x000b1;&#x000a0;1.4</td><td align="left">5.06&#x000a0;&#x000b1;&#x000a0;1.3</td><td align="left">0.556</td></tr><tr><td align="left">QUICKI</td><td align="left">0.34&#x000a0;&#x000b1;&#x000a0;0.01</td><td align="left">0.33&#x000a0;&#x000b1;&#x000a0;0.01</td><td align="left">0.195</td><td align="left">0.32&#x000a0;&#x000b1;&#x000a0;0.01</td><td align="left">0.33&#x000a0;&#x000b1;&#x000a0;0.01</td><td align="left">0.394</td></tr><tr><td align="left">composite WBISI</td><td align="left">3.46&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="left">3.04&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="left">0.253</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Insulinogenic index</td><td align="left">1.02&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="left">1.15&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="left">0.670</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">HOMA-&#x003b2;</td><td align="left">92.9&#x000a0;&#x000b1;&#x000a0;12.3</td><td align="left">1 16.5&#x000a0;&#x000b1;&#x000a0;14.4</td><td align="left">0.231</td><td align="left">57.5&#x000a0;&#x000b1;&#x000a0;11.2</td><td align="left">90.6&#x000a0;&#x000b1;&#x000a0;19.3</td><td align="left">0.198</td></tr><tr><td align="left">Blood glucose AUC on OGTT (0&#x02013;2&#x000a0;h) (mg&#x000a0;h/dL)</td><td align="left">270.3&#x000a0;&#x000b1;&#x000a0;8.7</td><td align="left">274.2&#x000a0;&#x000b1;&#x000a0;11.6</td><td align="left">0.788</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Insulin AUC on OGTT (0&#x02013;2&#x000a0;h) (&#x003bc;IU&#x000a0;h/mL)</td><td align="left">138.3&#x000a0;&#x000b1;&#x000a0;14.1</td><td align="left">165.4&#x000a0;&#x000b1;&#x000a0;14.6</td><td align="left">0.203</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">HbAlc (%)</td><td align="left">5.69&#x000a0;&#x000b1;&#x000a0;0.11</td><td align="left">5.59&#x000a0;&#x000b1;&#x000a0;0.14</td><td align="left">0.578</td><td align="left">7.32&#x000a0;&#x000b1;&#x000a0;0.17</td><td align="left">7.40&#x000a0;&#x000b1;&#x000a0;0.29</td><td align="left">0.861</td></tr><tr><td align="left">LDL-cholesterol (mg/dL)</td><td align="left">138.0&#x000a0;&#x000b1;&#x000a0;5.0</td><td align="left">124.5&#x000a0;&#x000b1;&#x000a0;6.9</td><td align="left">0.125</td><td align="left">121.3&#x000a0;&#x000b1;&#x000a0;7.1</td><td align="left">121.0&#x000a0;&#x000b1;&#x000a0;8.0</td><td align="left">0.814</td></tr><tr><td align="left">HDL-cholesterol (mg/dL)</td><td align="left">51.6&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="left">48.7&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="left">0.283</td><td align="left">50.0&#x000a0;&#x000b1;&#x000a0;2.6</td><td align="left">52.0&#x000a0;&#x000b1;&#x000a0;4.4</td><td align="left">0.811</td></tr><tr><td align="left">Triglyceride (mg/dL)</td><td align="left">182.1&#x000a0;&#x000b1;&#x000a0;2.1</td><td align="left">163.4&#x000a0;&#x000b1;&#x000a0;12.1</td><td align="left">0.477</td><td align="left">145.3&#x000a0;&#x000b1;&#x000a0;19.8</td><td align="left">173.0&#x000a0;&#x000b1;&#x000a0;11.3</td><td align="left">0.228</td></tr><tr><td align="left">WBC (/&#x003bc;L)</td><td align="left">6009.1&#x000a0;&#x000b1;&#x000a0;317.9</td><td align="left">6026.3&#x000a0;&#x000b1;&#x000a0;343.7</td><td align="left">0.972</td><td align="left">54,625&#x000a0;&#x000b1;&#x000a0;432.3</td><td align="left">6643.8&#x000a0;&#x000b1;&#x000a0;392.0</td><td align="left">0.071</td></tr><tr><td align="left">RBC (10<sup>4</sup>/&#x003bc;L)</td><td align="left">485.7&#x000a0;&#x000b1;&#x000a0;7.9</td><td align="left">502.3&#x000a0;&#x000b1;&#x000a0;8.0</td><td align="left">0.159</td><td align="left">482.3&#x000a0;&#x000b1;&#x000a0;11.8</td><td align="left">421.1&#x000a0;&#x000b1;&#x000a0;14.0</td><td align="left">0.334</td></tr><tr><td align="left">Hb (g/dL)</td><td align="left">15.2&#x000a0;&#x000b1;&#x000a0;1.2</td><td align="left">15.7&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="left">0.116</td><td align="left">15.0&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="left">13.9&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="left">0.060</td></tr><tr><td align="left">Plt (10<sup>4</sup>/&#x003bc;L)</td><td align="left">24.1&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="left">22.6&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="left">0.087</td><td align="left">22.4&#x000a0;&#x000b1;&#x000a0;1.2</td><td align="left">21.5&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="left">0.963</td></tr><tr><td align="left">BUN (mg/dL)</td><td align="left">13.9&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="left">13.0&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="left">0.376</td><td align="left">27.5&#x000a0;&#x000b1;&#x000a0;1.5</td><td align="left">26.1&#x000a0;&#x000b1;&#x000a0;3.1</td><td align="left">0.234</td></tr><tr><td align="left">Creatinine (mg/dL)</td><td align="left">0.78&#x000a0;&#x000b1;&#x000a0;0.02</td><td align="left">0.82&#x000a0;&#x000b1;&#x000a0;0.03</td><td align="left">0.312</td><td align="left">1.15&#x000a0;&#x000b1;&#x000a0;0.12</td><td align="left">1.36&#x000a0;&#x000b1;&#x000a0;0.19</td><td align="left">0.130</td></tr><tr><td align="left">AST (IU/L)</td><td align="left">20.8&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="left">24.9&#x000a0;&#x000b1;&#x000a0;2.5</td><td align="left">0.117</td><td align="left">32.2&#x000a0;&#x000b1;&#x000a0;3.6</td><td align="left">24.4&#x000a0;&#x000b1;&#x000a0;4.3</td><td align="left">0.175</td></tr><tr><td align="left">ALT (IU/L)</td><td align="left">25.3&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="left">35.4&#x000a0;&#x000b1;&#x000a0;3.7</td><td align="left">0.089</td><td align="left">35.7&#x000a0;&#x000b1;&#x000a0;4.5</td><td align="left">23.1&#x000a0;&#x000b1;&#x000a0;4.8</td><td align="left">0.085</td></tr><tr><td align="left">LDH (IU/L)</td><td align="left">l49.0&#x000a0;&#x000b1;&#x000a0;4.9</td><td align="left">163.8&#x000a0;&#x000b1;&#x000a0;4.5</td><td align="left">0.198</td><td align="left">228.5&#x000a0;&#x000b1;&#x000a0;7.7</td><td align="left">209.4&#x000a0;&#x000b1;&#x000a0;9.4</td><td align="left">0.113</td></tr><tr><td align="left">Adiponectin (&#x003bc;g/mL)</td><td align="left">3.15&#x000a0;&#x000b1;&#x000a0;0.32</td><td align="left">2.36&#x000a0;&#x000b1;&#x000a0;0.34</td><td align="left">0.094</td><td align="left">3.36&#x000a0;&#x000b1;&#x000a0;0.93</td><td align="left">5.86&#x000a0;&#x000b1;&#x000a0;1.10</td><td align="left">0.345</td></tr><tr><td align="left">Leptin (ng/mL)</td><td align="left">5.51&#x000a0;&#x000b1;&#x000a0;0.92</td><td align="left">5.77&#x000a0;&#x000b1;&#x000a0;0.58</td><td align="left">0.813</td><td align="left">8.38&#x000a0;&#x000b1;&#x000a0;1.07</td><td align="left">9.69&#x000a0;&#x000b1;&#x000a0;1.31</td><td align="left">0.562</td></tr><tr><td align="left">Interleukin-6 (pg/mL)</td><td align="left">1.48&#x000a0;&#x000b1;&#x000a0;0.26</td><td align="left">1.40&#x000a0;&#x000b1;&#x000a0;0.1 1</td><td align="left">0.761</td><td align="left">2.48&#x000a0;&#x000b1;&#x000a0;0.46</td><td align="left">3.50&#x000a0;&#x000b1;&#x000a0;0.72</td><td align="left">0.309</td></tr><tr><td align="left">Tumor necrosis factor-&#x003b1; (pg/mL)</td><td align="left">1.64&#x000a0;&#x000b1;&#x000a0;0.21</td><td align="left">1.23&#x000a0;&#x000b1;&#x000a0;0.19</td><td align="left">0.278</td><td align="left">1.71&#x000a0;&#x000b1;&#x000a0;0.50</td><td align="left">2.32&#x000a0;&#x000b1;&#x000a0;0.39</td><td align="left">0.386</td></tr><tr><td align="left">High sensitivity C-reactive protein (ng/mL)</td><td align="left">907.14&#x000a0;&#x000b1;&#x000a0;259.9</td><td align="left">607.9&#x000a0;&#x000b1;&#x000a0;107.1</td><td align="left">0.331</td><td align="left">1787.7&#x000a0;&#x000b1;&#x000a0;456.5</td><td align="left">2136.9&#x000a0;&#x000b1;&#x000a0;346.5</td><td align="left">0.265</td></tr><tr><td align="left">Cystatin C (mg/L)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">1.12&#x000a0;&#x000b1;&#x000a0;0.09</td><td align="left">1.65&#x000a0;&#x000b1;&#x000a0;0.16</td><td align="left">0.443</td></tr><tr><td align="left">U-albumin creatinine ratio (mg/g&#x000b7;Cre)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">329.6&#x000a0;&#x000b1;&#x000a0;252.5</td><td align="left">152.8&#x000a0;&#x000b1;&#x000a0;64.8</td><td align="left">0.307</td></tr></tbody></table><table-wrap-foot><fn id="sp0085"><p>The subjects' pre-clinical and biological characteristics. Values are expressed as mean&#x000a0;&#x000b1;&#x000a0;S.D. or numbers of subjects.</p></fn><fn id="sp0090"><p>HOMA-IR&#x000a0;=&#x000a0;the homeostasis model assessment of insulin resistance. QUICKI&#x000a0;=&#x000a0;quantitative insulin sensitivity check index. WBISI&#x000a0;=&#x000a0;whole body insulin sensitivity index. HOMA-p&#x000a0;=&#x000a0;the homeostasis model assessment of p-cell function. LDL&#x000a0;=&#x000a0;low-density lipoprotein. HDL&#x000a0;=&#x000a0;high-density lipoprotein. WBC&#x000a0;=&#x000a0;white blood cells. RBC&#x000a0;=&#x000a0;red blood cells. Hb&#x000a0;=&#x000a0;hemoglobin. Plt&#x000a0;=&#x000a0;platelets. BUN&#x000a0;=&#x000a0;blood urea nitrogen. AST&#x000a0;=&#x000a0;aspartic aminotransferase. ALT&#x000a0;=&#x000a0;alanine aminotransferase. LDH&#x000a0;=&#x000a0;lactate dehydrogenase.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0010" position="float"><label>Table&#x000a0;2</label><caption><p>Primary outcomes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="8" align="left">Metabolic syndrome<hr/></th></tr><tr><th align="left">Adiposity</th><th colspan="4" align="left">No treatment<hr/></th><th colspan="3" align="left">MES&#x000a0;+&#x000a0;HS<hr/></th></tr><tr><th align="left">Baseline</th><th align="left">No treatment</th><th align="left">&#x00394; no treat</th><th align="left">Baseline</th><th align="left">MES&#x000a0;+&#x000a0;HS</th><th align="left">&#x00394;MES&#x000a0;+&#x000a0;HS</th><th align="left">p value</th></tr></thead><tbody><tr><td align="left">Visceral fat area (cm<sup>2</sup>)</td><td align="char">148.4&#x000a0;&#x000b1;&#x000a0;6.4</td><td align="char">143.2&#x000a0;&#x000b1;&#x000a0;6.8</td><td align="char">&#x02212;&#x000a0;5.2</td><td align="char">147.4&#x000a0;&#x000b1;&#x000a0;6.6</td><td align="char">134.7&#x000a0;&#x000b1;&#x000a0;6.4</td><td align="char">&#x02212;&#x000a0;12.7</td><td align="char">0.037</td></tr><tr><td align="left">SubQ fat area (cm<sup>2</sup>)</td><td align="char">191.7&#x000a0;&#x000b1;&#x000a0;9.5</td><td align="char">191.0&#x000a0;&#x000b1;&#x000a0;9.6</td><td align="char">&#x02212;&#x000a0;0.7</td><td align="char">190.3&#x000a0;&#x000b1;&#x000a0;9.1</td><td align="char">187.4&#x000a0;&#x000b1;&#x000a0;8.5</td><td align="char">&#x02212;&#x000a0;2.9</td><td align="char">0.321</td></tr><tr><td align="left">Total fat area (cm<sup>2</sup>)</td><td align="char">340.1&#x000a0;&#x000b1;&#x000a0;13.2</td><td align="char">334.3&#x000a0;&#x000b1;&#x000a0;13.0</td><td align="char">&#x02212;&#x000a0;5.9</td><td align="char">337.7&#x000a0;&#x000b1;&#x000a0;12.7</td><td align="char">322.1&#x000a0;&#x000b1;&#x000a0;12.0</td><td align="char">&#x02212;&#x000a0;15.6</td><td align="char">0.019</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)</td><td align="char">26.8&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="char">26.7&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="char">&#x02212;&#x000a0;0.04</td><td align="char">26.8&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="char">25.8&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="char">&#x02212;&#x000a0;0.10</td><td align="char">0.328</td></tr><tr><td align="left">Wc (cm)</td><td align="char">94.1&#x000a0;&#x000b1;&#x000a0;1.0</td><td align="char">93.9&#x000a0;&#x000b1;&#x000a0;1.0</td><td align="char">&#x02212;&#x000a0;0.2</td><td align="char">93.9&#x000a0;&#x000b1;&#x000a0;1.1</td><td align="char">92.9&#x000a0;&#x000b1;&#x000a0;1.1</td><td align="char">&#x02212;&#x000a0;1.0</td><td align="char">0.033</td></tr><tr><td colspan="8" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="8" align="left"><italic>Glucose control</italic></td></tr><tr><td align="left">Blood glucose at 0&#x000a0;min (mg/dL)</td><td align="char">112.3&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="char">110.1&#x000a0;&#x000b1;&#x000a0;2.4</td><td align="char">&#x02212;&#x000a0;2.2</td><td align="char">112.7&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="char">106.7&#x000a0;&#x000b1;&#x000a0;2.5</td><td align="char">&#x02212;&#x000a0;6.0</td><td align="char">0.029</td></tr><tr><td align="left">Insulin at 0&#x000a0;min (&#x003bc;IU/mL)</td><td align="char">11.4&#x000a0;&#x000b1;&#x000a0;1.0</td><td align="char">11.7&#x000a0;&#x000b1;&#x000a0;1.0</td><td align="char">0.3</td><td align="char">10.4&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="char">9.3&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="char">&#x02212;&#x000a0;l.l</td><td align="char">0.049</td></tr><tr><td align="left">HOMA-IR</td><td align="char">3.2&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="char">3.2&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="char">0.05</td><td align="char">2.9&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="char">2.5&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="char">&#x02212;&#x000a0;0.4</td><td align="char">0.024</td></tr><tr><td align="left">Insulinogenic index</td><td align="char">1.7&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="char">1.4&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="char">&#x02212;&#x000a0;0.3</td><td align="char">1.7&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="char">1.0&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="char">&#x02212;&#x000a0;0.7</td><td align="char">0.042</td></tr><tr><td align="left">HOMA-&#x003b2;</td><td align="char">87.8&#x000a0;&#x000b1;&#x000a0;9.0</td><td align="char">88.8&#x000a0;&#x000b1;&#x000a0;7.3</td><td align="char">1.0</td><td align="char">78.7&#x000a0;&#x000b1;&#x000a0;6.5</td><td align="char">84.0&#x000a0;&#x000b1;&#x000a0;6.7</td><td align="char">5.3</td><td align="char">0.732</td></tr><tr><td align="left">QUICKI</td><td align="char">0.33&#x000a0;&#x000b1;&#x000a0;0.01</td><td align="char">0.33&#x000a0;&#x000b1;&#x000a0;0.01</td><td align="char">&#x02212;&#x000a0;0.003</td><td align="char">0.33&#x000a0;&#x000b1;&#x000a0;0.01</td><td align="char">0.34&#x000a0;&#x000b1;&#x000a0;0.01</td><td align="char">0.01</td><td align="char">0.09</td></tr><tr><td align="left">Composite WBISI</td><td align="char">3.2&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="char">3.5&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="char">0.3</td><td align="char">3.3&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="char">4.0&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="char">0.7</td><td align="char">0.029</td></tr><tr><td align="left">Glucose AUC</td><td align="char">334.2&#x000a0;&#x000b1;&#x000a0;10.6</td><td align="char">330.4&#x000a0;&#x000b1;&#x000a0;12.3</td><td align="char">&#x02212;&#x000a0;3.8</td><td align="char">337.2&#x000a0;&#x000b1;&#x000a0;12.4</td><td align="char">325.1&#x000a0;&#x000b1;&#x000a0;12.9</td><td align="char">&#x02212;&#x000a0;12.1</td><td align="char">0.150</td></tr><tr><td align="left">IRI AUC</td><td align="char">152.6&#x000a0;&#x000b1;&#x000a0;10.6</td><td align="char">148.1&#x000a0;&#x000b1;&#x000a0;12.2</td><td align="char">&#x02212;&#x000a0;4.5</td><td align="char">145.3&#x000a0;&#x000b1;&#x000a0;9.6</td><td align="char">139.4&#x000a0;&#x000b1;&#x000a0;9.7</td><td align="char">&#x02212;&#x000a0;5.9</td><td align="char">0.385</td></tr><tr><td align="left">HbAlc (%)</td><td align="char">5.24&#x000a0;&#x000b1;&#x000a0;0.09</td><td align="char">5.23&#x000a0;&#x000b1;&#x000a0;0.08</td><td align="char">&#x02212;&#x000a0;0.01</td><td align="char">5.29&#x000a0;&#x000b1;&#x000a0;0.08</td><td align="char">5.22&#x000a0;&#x000b1;&#x000a0;0.09</td><td align="char">&#x02212;&#x000a0;0.07</td><td align="char">0.143</td></tr><tr><td colspan="8" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="8" align="left">Type 2 diabetes mellitus</td></tr><tr><td colspan="8"><hr/></td></tr><tr><td align="left">Adiposity</td><td colspan="4" align="left">No treatment<hr/></td><td colspan="3" align="left">MES&#x000a0;+&#x000a0;HS<hr/></td></tr><tr><td colspan="8"><hr/></td></tr><tr><td align="left">Baseline</td><td align="left">No treatment</td><td align="left">&#x00394; no treat</td><td align="left">Baseline</td><td align="left">MES&#x000a0;+&#x000a0;HS</td><td align="left">&#x00394;MES&#x000a0;+&#x000a0;HS</td><td align="left">p value</td></tr><tr><td colspan="8"><hr/></td></tr><tr><td align="left">Visceral fat area (cm<sup>2</sup>)</td><td align="char">186.0&#x000a0;&#x000b1;&#x000a0;9.8</td><td align="char">187.1&#x000a0;&#x000b1;&#x000a0;9.3</td><td align="char">l.l</td><td align="char">191.8&#x000a0;&#x000b1;&#x000a0;9.5</td><td align="char">179.9&#x000a0;&#x000b1;&#x000a0;7.0</td><td align="char">&#x02212;&#x000a0;20.9</td><td align="char">0.003</td></tr><tr><td align="left">SubO fat area (cm<sup>2</sup>)</td><td align="char">160.4&#x000a0;&#x000b1;&#x000a0;11.1</td><td align="char">170.0&#x000a0;&#x000b1;&#x000a0;12.6</td><td align="char">9.6</td><td align="char">167.8&#x000a0;&#x000b1;&#x000a0;12.4</td><td align="char">169.9&#x000a0;&#x000b1;&#x000a0;12.5</td><td align="char">2.1</td><td align="char">0.041</td></tr><tr><td align="left">total fat area (cm<sup>2</sup>)</td><td align="char">346.4&#x000a0;&#x000b1;&#x000a0;19.2</td><td align="char">357.1&#x000a0;&#x000b1;&#x000a0;20.7</td><td align="char">10.7</td><td align="char">359.6&#x000a0;&#x000b1;&#x000a0;20.6</td><td align="char">340.8&#x000a0;&#x000b1;&#x000a0;17.6</td><td align="char">&#x02212;&#x000a0;18.8</td><td align="char">0.005</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)</td><td align="char">27.8&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="char">27.8&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="char">&#x02212;&#x000a0;0.02</td><td align="char">27.8&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="char">27.4&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="char">&#x02212;&#x000a0;0.4</td><td align="char">0.027</td></tr><tr><td align="left">Wc (cm)</td><td align="char">97.7&#x000a0;&#x000b1;&#x000a0;2.0</td><td align="char">100.5&#x000a0;&#x000b1;&#x000a0;3.1</td><td align="char">2.8</td><td align="char">97.9&#x000a0;&#x000b1;&#x000a0;2.1</td><td align="char">95.2&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="char">&#x02212;&#x000a0;2.7</td><td align="char">0.021</td></tr><tr><td colspan="8" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="8" align="left"><italic>Glucose control</italic></td></tr><tr><td align="left">Fasting blood glucose (mg/dL)</td><td align="char">147.7&#x000a0;&#x000b1;&#x000a0;7.1</td><td align="char">148.2&#x000a0;&#x000b1;&#x000a0;6.2</td><td align="char">0.5</td><td align="char">148.6&#x000a0;&#x000b1;&#x000a0;6.2</td><td align="char">133.1&#x000a0;&#x000b1;&#x000a0;5.4</td><td align="char">&#x02212;&#x000a0;15.5</td><td align="char">0.000&#x000a0;l</td></tr><tr><td align="left">Fasting insulin (&#x003bc;IU/mL)</td><td align="char">14.3&#x000a0;&#x000b1;&#x000a0;2.1</td><td align="char">13.6&#x000a0;&#x000b1;&#x000a0;1.6</td><td align="char">&#x02212;&#x000a0;0.7</td><td align="char">15.0&#x000a0;&#x000b1;&#x000a0;2.0</td><td align="char">11.1&#x000a0;&#x000b1;&#x000a0;1.6</td><td align="char">&#x02212;&#x000a0;3.9</td><td align="char">0.024</td></tr><tr><td align="left">HOMA-IR</td><td align="char">5.5&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="char">5.1&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="char">&#x02212;&#x000a0;0.4</td><td align="char">5.7&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="char">3.8&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="char">&#x02212;&#x000a0;1.9</td><td align="char">0.009</td></tr><tr><td align="left">HOMA-&#x003b2;</td><td align="char">73.2&#x000a0;&#x000b1;&#x000a0;11.4</td><td align="char">65.4&#x000a0;&#x000b1;&#x000a0;8.4</td><td align="char">&#x02212;&#x000a0;7.8</td><td align="char">70.8&#x000a0;&#x000b1;&#x000a0;9.4</td><td align="char">66.8&#x000a0;&#x000b1;&#x000a0;12.4</td><td align="char">&#x02212;&#x000a0;4.0</td><td align="char">0.362</td></tr><tr><td align="left">HbAlc (%)</td><td align="char">7.35&#x000a0;&#x000b1;&#x000a0;0.17</td><td align="char">7.29&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="char">&#x02212;&#x000a0;0.06</td><td align="char">7.27&#x000a0;&#x000b1;&#x000a0;0.17</td><td align="char">6.78&#x000a0;&#x000b1;&#x000a0;0.14</td><td align="char">&#x02212;&#x000a0;0.49</td><td align="char">0.009</td></tr></tbody></table><table-wrap-foot><fn><p>The results of MES&#x000a0;+&#x000a0;HS intervention data compared to no treatment period. Values are expressed as mean&#x000a0;&#x000b1;&#x000a0;S.D. Other abbreviations are the same as <xref rid="t0005" ref-type="table">Table&#x000a0;1</xref>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0015" position="float"><label>Table&#x000a0;3</label><caption><p>Secondary outcomes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="8" align="left">Metabolic syndrome<hr/></th></tr><tr><th align="left">Inflammation<hr/></th><th colspan="4" align="left">No treatment<hr/></th><th colspan="3" align="left">MES&#x000a0;+&#x000a0;HS<hr/></th></tr><tr><th align="left"/><th align="left">Baseline</th><th align="left">No treatment</th><th align="left">&#x00394; no treat</th><th align="left">Baseline</th><th align="left">MES&#x000a0;+&#x000a0;HS</th><th align="left">&#x00394;MES&#x000a0;+&#x000a0;HS</th><th align="left">p value</th></tr></thead><tbody><tr><td align="left">hs-CRP (ng/mL)</td><td align="char">767.9&#x000a0;&#x000b1;&#x000a0;153.6</td><td align="char">1516.8&#x000a0;&#x000b1;&#x000a0;402.3</td><td align="char">748.9</td><td align="char">1549.3&#x000a0;&#x000b1;&#x000a0;420.6</td><td align="char">715.0&#x000a0;&#x000b1;&#x000a0;114.0</td><td align="char">&#x02212;&#x000a0;834.3</td><td align="char">0.025</td></tr><tr><td align="left">Adiponectin (&#x003bc;g/mL)</td><td align="char">2.8&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="char">2.7&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="char">&#x02212;&#x000a0;0.1</td><td align="char">2.9&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="char">3.1&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="char">0.2</td><td align="char">0.020</td></tr><tr><td align="left">Leptin (ng/mL)</td><td align="char">5.6&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="char">5.5&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="char">&#x02212;&#x000a0;0.1</td><td align="char">5.5&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="char">5.0&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="char">&#x02212;&#x000a0;0.5</td><td align="char">0.120</td></tr><tr><td align="left">TNF-&#x003b1; (pg/mL)</td><td align="char">1.4&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="char">1.3&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="char">&#x02212;&#x000a0;0.1</td><td align="char">1.5&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="char">1.3&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="char">&#x02212;&#x000a0;0.2</td><td align="char">0.020</td></tr><tr><td align="left">IL-6 (pg/mL)</td><td align="char">1.5&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="char">1.6&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="char">0.1</td><td align="char">1.8&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="char">1.3&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="char">&#x02212;&#x000a0;0.5</td><td align="char">0.036</td></tr><tr><td colspan="8" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="8" align="left"><italic>Blood pressure</italic></td></tr><tr><td align="left">Systolic blood pressure (mm&#x000a0;Hg)</td><td align="char">135.5&#x000a0;&#x000b1;&#x000a0;2.5</td><td align="char">134.9&#x000a0;&#x000b1;&#x000a0;2.5</td><td align="char">&#x02212;&#x000a0;0.6</td><td align="char">135.0&#x000a0;&#x000b1;&#x000a0;2.7</td><td align="char">129.3&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="char">&#x02212;&#x000a0;5.7</td><td align="char">0.034</td></tr><tr><td align="left">Diastolic blood pressure (mm&#x000a0;Hg)</td><td align="char">85.8&#x000a0;&#x000b1;&#x000a0;1.7</td><td align="char">86.3&#x000a0;&#x000b1;&#x000a0;1.4</td><td align="char">&#x02212;&#x000a0;0.5</td><td align="char">85.0&#x000a0;&#x000b1;&#x000a0;1.6</td><td align="char">82.6&#x000a0;&#x000b1;&#x000a0;1.3</td><td align="char">&#x02212;&#x000a0;2.4</td><td align="char">0.038</td></tr><tr><td align="left">Heart rate (bpm)</td><td align="char">68.9&#x000a0;&#x000b1;&#x000a0;1.4</td><td align="char">70.2&#x000a0;&#x000b1;&#x000a0;1.5</td><td align="char">1.3</td><td align="char">69.9&#x000a0;&#x000b1;&#x000a0;1.5</td><td align="char">69.6&#x000a0;&#x000b1;&#x000a0;1.4</td><td align="char">&#x02212;&#x000a0;0.3</td><td align="char">0.237</td></tr><tr><td colspan="8" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="8" align="left"><italic>Others</italic></td></tr><tr><td align="left">WBC (/&#x003bc;L)</td><td align="char">6015.0&#x000a0;&#x000b1;&#x000a0;239.2</td><td align="char">5990.0&#x000a0;&#x000b1;&#x000a0;287.9</td><td align="char">&#x02212;&#x000a0;25.0</td><td align="char">6112.5&#x000a0;&#x000b1;&#x000a0;254.02</td><td align="char">5665.0&#x000a0;&#x000b1;&#x000a0;256.5</td><td align="char">&#x02212;&#x000a0;447.5</td><td align="char">0.037</td></tr><tr><td align="left">Hb (g/dL)</td><td align="char">15.5&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="char">15.6&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="char">0.1</td><td align="char">15.6&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="char">15.4&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="char">&#x02212;&#x000a0;0.2</td><td align="char">0.357</td></tr><tr><td align="left">Ht (%)</td><td align="char">46.7&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="char">47.7&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="char">1.0</td><td align="char">47.2&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="char">47.4&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="char">0.2</td><td align="char">0.956</td></tr><tr><td align="left">Plt (&#x000d7;&#x000a0;10<sup>4</sup>/&#x003bc;L)</td><td align="char">22.8&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="char">22.&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="char">0.1</td><td align="char">22.4&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="char">23.1&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="char">0.7</td><td align="char">0.275</td></tr><tr><td align="left">AST (U/L)</td><td align="char">22.7&#x000a0;&#x000b1;&#x000a0;1.3</td><td align="char">24.8&#x000a0;&#x000b1;&#x000a0;1.3</td><td align="char">2.1</td><td align="char">23.3&#x000a0;&#x000b1;&#x000a0;1.4</td><td align="char">23.1&#x000a0;&#x000b1;&#x000a0;1.4</td><td align="char">&#x02212;&#x000a0;0.2</td><td align="char">0.104</td></tr><tr><td align="left">ALT (U/L)</td><td align="char">30.5&#x000a0;&#x000b1;&#x000a0;2.2</td><td align="char">31.4&#x000a0;&#x000b1;&#x000a0;2.1</td><td align="char">0.9</td><td align="char">30.3&#x000a0;&#x000b1;&#x000a0;2.2</td><td align="char">26.4&#x000a0;&#x000b1;&#x000a0;1.7</td><td align="char">&#x02212;&#x000a0;3.9</td><td align="char">0.012</td></tr><tr><td align="left">AST/ALT</td><td align="char">0.80&#x000a0;&#x000b1;&#x000a0;0.04</td><td align="char">0.84&#x000a0;&#x000b1;&#x000a0;0.04</td><td align="char">0.04</td><td align="char">0.83&#x000a0;&#x000b1;&#x000a0;0.04</td><td align="char">0.94&#x000a0;&#x000b1;&#x000a0;0.05</td><td align="char">0.11</td><td align="char">0.023</td></tr><tr><td align="left">L/S ratio</td><td align="char">0.994&#x000a0;&#x000b1;&#x000a0;0.001</td><td align="char">0.999&#x000a0;&#x000b1;&#x000a0;0.001</td><td align="char">0.005</td><td align="char">0.996&#x000a0;&#x000b1;&#x000a0;0.002</td><td align="char">1.092&#x000a0;&#x000b1;&#x000a0;0.002</td><td align="char">0.096</td><td align="char">0.003</td></tr><tr><td align="left">LDH (U/L)</td><td align="char">156.0&#x000a0;&#x000b1;&#x000a0;3.6</td><td align="char">162.4&#x000a0;&#x000b1;&#x000a0;3.0</td><td align="char">6.4</td><td align="char">156.4&#x000a0;&#x000b1;&#x000a0;3.5</td><td align="char">161.3&#x000a0;&#x000b1;&#x000a0;3.5</td><td align="char">4.9</td><td align="char">0.310</td></tr><tr><td align="left">BUN (mg/dL)</td><td align="char">13.6&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="char">14.3&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="char">0.7</td><td align="char">14.0&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="char">14.2&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="char">0.2</td><td align="char">0.139</td></tr><tr><td align="left">Cre (mg/dL)</td><td align="char">0.80&#x000a0;&#x000b1;&#x000a0;0.02</td><td align="char">0.82&#x000a0;&#x000b1;&#x000a0;0.02</td><td align="char">0.02</td><td align="char">0.81&#x000a0;&#x000b1;&#x000a0;0.02</td><td align="char">0.79&#x000a0;&#x000b1;&#x000a0;0.02</td><td align="char">&#x02212;&#x000a0;0.02</td><td align="char">0.010</td></tr><tr><td align="left">LDL-C (mg/dL)</td><td align="char">131.6&#x000a0;&#x000b1;&#x000a0;4.4</td><td align="char">131.9&#x000a0;&#x000b1;&#x000a0;4.0</td><td align="char">0.3</td><td align="char">133.3&#x000a0;&#x000b1;&#x000a0;4.0</td><td align="char">126.1&#x000a0;&#x000b1;&#x000a0;3.8</td><td align="char">&#x02212;&#x000a0;7.2</td><td align="char">0.040</td></tr><tr><td align="left">HDL-C (mg/dL)</td><td align="char">50.4&#x000a0;&#x000b1;&#x000a0;1.3</td><td align="char">51.4&#x000a0;&#x000b1;&#x000a0;1.5</td><td align="char">1.0</td><td align="char">50.4&#x000a0;&#x000b1;&#x000a0;1.5</td><td align="char">50.2&#x000a0;&#x000b1;&#x000a0;1.5</td><td align="char">&#x02212;&#x000a0;0.2</td><td align="char">0.221</td></tr><tr><td align="left">TG (mg/dL)</td><td align="char">171.5&#x000a0;&#x000b1;&#x000a0;13.0</td><td align="char">164.4&#x000a0;&#x000b1;&#x000a0;14.6</td><td align="char">&#x02212;&#x000a0;7.1</td><td align="char">156.1&#x000a0;&#x000b1;&#x000a0;10.6</td><td align="char">150.0&#x000a0;&#x000b1;&#x000a0;11.3</td><td align="char">&#x02212;&#x000a0;6.1</td><td align="char">0.540</td></tr><tr><td colspan="8" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="8" align="left">Type 2 diabetes mellitus</td></tr><tr><td colspan="8"><hr/></td></tr><tr><td align="left">Inflammation</td><td colspan="4" align="left">No treatment<hr/></td><td colspan="3" align="left">MES&#x000a0;+&#x000a0;HS<hr/></td></tr><tr><td colspan="8"><hr/></td></tr><tr><td align="left">Baseline</td><td align="left">No treatment</td><td align="left">&#x00394; no treat</td><td align="left">Baseline</td><td align="left">MES&#x000a0;+&#x000a0;HS</td><td align="left">&#x00394;MES&#x000a0;+&#x000a0;HS</td><td align="left">p value</td></tr><tr><td colspan="8"><hr/></td></tr><tr><td align="left">hs-CRP (ng/mL)</td><td align="char">3923.3&#x000a0;&#x000b1;&#x000a0;1779.0</td><td align="char">4206.5&#x000a0;&#x000b1;&#x000a0;1932.1</td><td align="left">283.2</td><td align="char">4158.1&#x000a0;&#x000b1;&#x000a0;1920.7</td><td align="char">3969.5&#x000a0;&#x000b1;&#x000a0;1882.4</td><td align="char">&#x02212;&#x000a0;188.6</td><td align="char">0.047</td></tr><tr><td align="left">Adiponectin (&#x003bc;g/mL)</td><td align="char">4.7&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="char">3.8&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="left">&#x02212;&#x000a0;0.9</td><td align="char">3.9&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="char">4.2&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="char">0.3</td><td align="char">0.003</td></tr><tr><td align="left">Leptin (ng/mL)</td><td align="char">8.9&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="char">10.5&#x000a0;&#x000b1;&#x000a0;1.1</td><td align="left">1.6</td><td align="char">10.2&#x000a0;&#x000b1;&#x000a0;1.1</td><td align="char">9.1&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="char">&#x02212;&#x000a0;1.1</td><td align="char">0.003</td></tr><tr><td align="left">TNF-&#x003b1; (pg/mL)</td><td align="char">2.0&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="char">2.7&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="left">0.7</td><td align="char">2.5&#x000a0;&#x000b1;&#x000a0;0.5</td><td align="char">2.0&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="char">&#x02212;&#x000a0;0.5</td><td align="char">0.001</td></tr><tr><td align="left">IL-6 (pg/mL)</td><td align="char">3.0&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="char">2.8&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="left">&#x02212;&#x000a0;0.2</td><td align="char">2.8&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="char">2.9&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="char">0.1</td><td align="char">0.230</td></tr><tr><td colspan="8" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="8" align="left"><italic>Blood pressure</italic></td></tr><tr><td align="left">Systolic blood pressure (mm&#x000a0;Hg)</td><td align="char">143.0&#x000a0;&#x000b1;&#x000a0;3.3</td><td align="char">142.4&#x000a0;&#x000b1;&#x000a0;3.0</td><td align="left">&#x02212;&#x000a0;0.6</td><td align="char">136.7&#x000a0;&#x000b1;&#x000a0;3.0</td><td align="char">129.1&#x000a0;&#x000b1;&#x000a0;2.5</td><td align="char">&#x02212;&#x000a0;7.6</td><td align="char">0.013</td></tr><tr><td align="left">Diastolic blood pressure (mm&#x000a0;Hg)</td><td align="char">74.7&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="char">73.6&#x000a0;&#x000b1;&#x000a0;1.9</td><td align="left">&#x02212;&#x000a0;1.1</td><td align="char">71.7&#x000a0;&#x000b1;&#x000a0;1.9</td><td align="char">66.5&#x000a0;&#x000b1;&#x000a0;2.0</td><td align="char">&#x02212;&#x000a0;5.2</td><td align="char">0.005</td></tr><tr><td align="left">Heart rate (bpm)</td><td align="char">70.1&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="char">70.6&#x000a0;&#x000b1;&#x000a0;1.5</td><td align="left">0.5</td><td align="char">69.9&#x000a0;&#x000b1;&#x000a0;1.6</td><td align="char">68.2&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="char">&#x02212;&#x000a0;1.7</td><td align="char">0.110</td></tr><tr><td colspan="8" align="left">&#x02028;&#x02028;</td></tr><tr><td colspan="8" align="left"><italic>Others</italic></td></tr><tr><td align="left">WBC (/&#x003bc;L)</td><td align="char">6030.3&#x000a0;&#x000b1;&#x000a0;301.3</td><td align="char">5975.8&#x000a0;&#x000b1;&#x000a0;259.2</td><td align="left">&#x02212;&#x000a0;54.5</td><td align="char">6041.1&#x000a0;&#x000b1;&#x000a0;250.6</td><td align="char">6144.1&#x000a0;&#x000b1;&#x000a0;250.6</td><td align="char">103.0</td><td align="char">0.512</td></tr><tr><td align="left">Hb (g/dL)</td><td align="char">14.5&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="char">14.2&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="left">&#x02212;&#x000a0;0.3</td><td align="char">14.3&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="char">14.3&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="char">&#x02212;&#x000a0;0.04</td><td align="char">0.283</td></tr><tr><td align="left">Ht (%)</td><td align="char">42.0&#x000a0;&#x000b1;&#x000a0;1.0</td><td align="char">41.3&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="left">&#x02212;&#x000a0;0.7</td><td align="char">41.7&#x000a0;&#x000b1;&#x000a0;1.0</td><td align="char">41.3&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="char">&#x02212;&#x000a0;0.4</td><td align="char">0.702</td></tr><tr><td align="left">Plt (&#x000d7;&#x000a0;10<sup>4</sup>/&#x003bc;L)</td><td align="char">19.3&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="char">18.4&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="left">&#x02212;&#x000a0;1.1</td><td align="char">18.0&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="char">19.8&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="char">1.8</td><td align="char">0.175</td></tr><tr><td align="left">AST (U/L)</td><td align="char">28.5&#x000a0;&#x000b1;&#x000a0;2.8</td><td align="char">27.2&#x000a0;&#x000b1;&#x000a0;2.2</td><td align="left">&#x02212;&#x000a0;1.3</td><td align="char">29.5&#x000a0;&#x000b1;&#x000a0;2.6</td><td align="char">26.2&#x000a0;&#x000b1;&#x000a0;2.1</td><td align="char">&#x02212;&#x000a0;3.3</td><td align="char">0.137</td></tr><tr><td align="left">ALT (U/L)</td><td align="char">29.7&#x000a0;&#x000b1;&#x000a0;3.5</td><td align="char">29.8&#x000a0;&#x000b1;&#x000a0;3.0</td><td align="left">0.1</td><td align="char">29.8&#x000a0;&#x000b1;&#x000a0;3.0</td><td align="char">22.7&#x000a0;&#x000b1;&#x000a0;1.5</td><td align="char">&#x02212;&#x000a0;7.1</td><td align="char">0.068</td></tr><tr><td align="left">AST/ALT</td><td align="char">1.08&#x000a0;&#x000b1;&#x000a0;0.06</td><td align="char">1.01&#x000a0;&#x000b1;&#x000a0;0.05</td><td align="left">&#x02212;&#x000a0;0.07</td><td align="char">1.09&#x000a0;&#x000b1;&#x000a0;0.06</td><td align="char">1.19&#x000a0;&#x000b1;&#x000a0;0.07</td><td align="char">0.09</td><td align="char">0.018</td></tr><tr><td align="left">L/S ratio</td><td align="char">0.965&#x000a0;&#x000b1;&#x000a0;0.001</td><td align="char">0.973&#x000a0;&#x000b1;&#x000a0;0.001</td><td align="left">0.008</td><td align="char">0.973&#x000a0;&#x000b1;&#x000a0;0.002</td><td align="char">1.084&#x000a0;&#x000b1;&#x000a0;0.002</td><td align="char">0.111</td><td align="char">0.032</td></tr><tr><td align="left">LDH (U/L)</td><td align="char">219.5&#x000a0;&#x000b1;&#x000a0;6.2</td><td align="char">204.3&#x000a0;&#x000b1;&#x000a0;4.3</td><td align="left">&#x02212;&#x000a0;15.2</td><td align="char">213.0&#x000a0;&#x000b1;&#x000a0;5.8</td><td align="char">200.5&#x000a0;&#x000b1;&#x000a0;4.2</td><td align="char">&#x02212;&#x000a0;12.5</td><td align="char">0.353</td></tr><tr><td align="left">BUN (mg/dL)</td><td align="char">21.6&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="char">20.9&#x000a0;&#x000b1;&#x000a0;1.7</td><td align="left">&#x02212;&#x000a0;0.7</td><td align="char">21.0&#x000a0;&#x000b1;&#x000a0;1.7</td><td align="char">19.5&#x000a0;&#x000b1;&#x000a0;1.6</td><td align="char">&#x02212;&#x000a0;1.5</td><td align="char">0.224</td></tr><tr><td align="left">Cre (mg/dL)</td><td align="char">1.2&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="char">1.2&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="left">0.02</td><td align="char">1.2&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="char">1.1&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="char">&#x02212;&#x000a0;0.1</td><td align="char">0.013</td></tr><tr><td align="left">LDL-C (mg/dL)</td><td align="char">121.2&#x000a0;&#x000b1;&#x000a0;5.3</td><td align="char">121.7&#x000a0;&#x000b1;&#x000a0;5.0</td><td align="left">0.5</td><td align="char">121.6&#x000a0;&#x000b1;&#x000a0;5.1</td><td align="char">112.4&#x000a0;&#x000b1;&#x000a0;4.7</td><td align="char">&#x02212;&#x000a0;9.2</td><td align="char">0.007</td></tr><tr><td align="left">HDL-C (mg/dL)</td><td align="char">51.0&#x000a0;&#x000b1;&#x000a0;2.5</td><td align="char">50.3&#x000a0;&#x000b1;&#x000a0;2.8</td><td align="left">&#x02212;&#x000a0;0.7</td><td align="char">49.9&#x000a0;&#x000b1;&#x000a0;2.7</td><td align="char">52.6&#x000a0;&#x000b1;&#x000a0;2.6</td><td align="char">2.7</td><td align="char">0.009</td></tr><tr><td align="left">TG (mg/dL)</td><td align="char">158.4&#x000a0;&#x000b1;&#x000a0;12.0</td><td align="char">162.4&#x000a0;&#x000b1;&#x000a0;10.3</td><td align="left">4.09&#x000a0;&#x000b1;&#x000a0;9.07</td><td align="char">161.7&#x000a0;&#x000b1;&#x000a0;11.6</td><td align="char">148.0&#x000a0;&#x000b1;&#x000a0;12.9</td><td align="char">&#x02212;&#x000a0;13.7</td><td align="char">0.109</td></tr><tr><td align="left">Cystatin C (mg/L)</td><td align="char">1.4&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="char">1.4&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="left">&#x02212;&#x000a0;0.005</td><td align="char">1.4&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="char">1.4&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="char">0.007</td><td align="char">0.358</td></tr><tr><td align="left">U-ACR (mg/g&#x022c5;Cre)</td><td align="char">199.4&#x000a0;&#x000b1;&#x000a0;135.8</td><td align="char">102.4&#x000a0;&#x000b1;&#x000a0;54.7</td><td align="left">&#x02212;&#x000a0;37.0</td><td align="char">194.4&#x000a0;&#x000b1;&#x000a0;136.0</td><td align="char">89.5&#x000a0;&#x000b1;&#x000a0;40.7</td><td align="char">&#x02212;&#x000a0;104.9</td><td align="char">0.047</td></tr></tbody></table><table-wrap-foot><fn id="sp0125"><p>The results of MES&#x000a0;+&#x000a0;HS intervention data compared to no treatment period. Values are expressed as mean&#x000a0;&#x000b1;&#x000a0;S.D.</p></fn><fn id="sp0130"><p>L/S ratio&#x000a0;=&#x000a0;Liver to spleen ratio on computed tomography.</p></fn><fn id="sp0135"><p>U-ACR&#x000a0;=&#x000a0;Urinary albumin creatinine ratio. Other abbreviations are the same as <xref rid="t0005" ref-type="table">Table&#x000a0;1</xref>.</p></fn></table-wrap-foot></table-wrap></floats-group></article>